107. 若年性特発性関節炎 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 447 / 薬物数 : 297 - (DrugBank : 57) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 146
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
(1-3)-beta-D-Glucan (BDG) assay (Fungitell)
Centre Hospitalier Universitaire, Amiens
2019 - NCT03984669 France;
(1-3)-ß-D-Glucan (BDG) assay (Fungitell)
Centre Hospitalier Universitaire, Amiens
2019 - NCT03984669 France;
- SOLUZIONE INIETTABILE IN SIRINGHE PRE-RIEMPITE- USO SOTTOCUTANEO- SIRINGA PRERIEMPITA (0,4ML)- 2 SIRINGHE PRE-RIEMPITE + 2 TAMPONI IMBEVUTI DI ALCOOL
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
0.4mL prefilled syringes
Bristol-Myers Squibb International Corporation
2013 Phase 3 EUCTR2012-003195-39-IT Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-ES Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-DE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-BE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- Phase 3 EUCTR2012-003195-39-FR Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- - EUCTR2012-003195-39-Outside-EU/EEA Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
0.7mL prefilled syringes
Bristol-Myers Squibb International Corporation
2013 Phase 3 EUCTR2012-003195-39-IT Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-ES Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-DE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-BE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- Phase 3 EUCTR2012-003195-39-FR Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- - EUCTR2012-003195-39-Outside-EU/EEA Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
1mL prefilled syringes
Bristol-Myers Squibb International Corporation
2013 Phase 3 EUCTR2012-003195-39-IT Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-ES Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-DE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-BE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- Phase 3 EUCTR2012-003195-39-FR Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- - EUCTR2012-003195-39-Outside-EU/EEA Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
98-92-0
UMC Utrecht
2019 Phase 1;Phase 2 EUCTR2018-002245-11-NL Netherlands;
- Phase 1;Phase 2 EUCTR2016-003643-10-NL Netherlands;
ABT-494
ABBVIE DEUTSCHLAND GMBH & CO. KG
2019 Phase 1 EUCTR2018-000715-25-IT Germany;Hungary;Italy;Spain;United States;
AbbVie Deutschland GmbH & Co. KG
2019 Phase 1;Phase 3 EUCTR2018-000715-25-ES Germany;Hungary;Italy;Spain;United States;
2019 Phase 1 EUCTR2018-000715-25-HU Germany;Hungary;Italy;Spain;United States;
2019 Phase 1 EUCTR2018-000715-25-DE Germany;Hungary;Italy;Spain;United States;
ACZ885
NOVARTIS FARMA
2009 - EUCTR2008-008008-42-IT Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-IT Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
NOVARTIS FARMA S.p.A.
2014 Phase 3;Phase 4 EUCTR2013-004867-29-IT Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
NOVARTIS PHARMA AG
2006 - EUCTR2006-001834-42-IT France;Italy;United Kingdom;
Novartis
2006 Phase 1/Phase 2 NCT00426218 Italy;
Novartis Farmaceutica, S.A.
2013 - EUCTR2012-003054-92-ES Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Novartis Farmacéutica S.A.
2009 Phase 3 EUCTR2008-005476-27-ES Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-ES Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-ES Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
Novartis Farmacéutica, S.A.
2014 Phase 3;Phase 4 EUCTR2013-004867-29-ES Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
Novartis Pharma K.K.
2015 Phase 3 JPRN-JapicCTI-152865 -
Novartis Pharma S.A.S
2014 Phase 4 EUCTR2014-002872-95-FR France;
Novartis Pharma Services AG
2014 Phase 3;Phase 4 EUCTR2013-004867-29-SE Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
2014 Phase 3;Phase 4 EUCTR2013-004867-29-NL Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
2014 Phase 3;Phase 4 EUCTR2013-004867-29-HU Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
2014 Phase 3;Phase 4 EUCTR2013-004867-29-DE Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
2014 Phase 3;Phase 4 EUCTR2013-004867-29-BE Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
2014 Phase 3;Phase 4 EUCTR2013-004867-29-AT Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
2013 - EUCTR2012-003054-92-CZ Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2012-003054-92-AT Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2010 - EUCTR2008-008008-42-GR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-008008-42-AT Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2010 - EUCTR2008-005479-82-GR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005476-27-GR Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005476-27-GB Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005479-82-FR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005479-82-BE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005476-27-FR Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-SE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Russian Federation;Spain;Swaziland;Sweden;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-NL Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-HU Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-GB Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-FR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-DK Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-DE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-BE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-005479-82-SE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-HU Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-GB Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-DK Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-DE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-AT Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-SE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-HU Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-DK Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-DE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-BE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2012-003054-92-BE Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2008-008008-42-NO Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-005479-82-NO Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-005476-27-NO Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
- - EUCTR2008-005479-82-Outside-EU/EEA Argentina;Brazil;Canada;Israel;Peru;Switzerland;Turkey;United States;
- - EUCTR2008-005476-27-Outside-EU/EEA Argentina;Brazil;Israel;Peru;Switzerland;Turkey;United States;
Novartis PharmaServices AG
- - EUCTR2008-008008-42-Outside-EU/EEA Argentina;Brazil;Canada;Israel;Peru;Russian Federation;South Africa;Switzerland;Turkey;United States;
Novartis Pharmaceuticals
2013 Phase 3 NCT01676948 Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
ACZ885 150 mg (Canakinumab)
Novartis Pharmaceuticals
2014 Phase 3 NCT02296424 Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
ACZ885 Drug Substance
Novartis Pharma Services AG
2007 Phase 2 EUCTR2006-001834-42-GB France;Italy;United Kingdom;
2007 - EUCTR2006-001834-42-FR France;Italy;United Kingdom;
ACZ885G
NOVARTIS FARMA
2009 - EUCTR2008-005476-27-IT Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
AIN457
NOVARTIS PHARMA AG
2019 Phase 3 EUCTR2018-002521-30-IT Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
- Phase 3 EUCTR2016-003761-26-IT Belgium;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
Novartis Farmacéutica S.A.
2017 Phase 3 EUCTR2016-003761-26-ES Belgium;Germany;Italy;Netherlands;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
Novartis Farmacéutica, S.A.
2019 Phase 3 EUCTR2018-002521-30-ES Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
Novartis Pharma AG
2019 Phase 3 EUCTR2018-002521-30-DE Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
2017 Phase 3 EUCTR2016-003761-26-PL Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003761-26-GB Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003761-26-DE Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003761-26-BE Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2018-002521-30-PL Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
- Phase 3 EUCTR2018-002521-30-BE Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
Novartis Pharmaceuticals
2019 Phase 3 NCT03769168 Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
2017 Phase 3 NCT03031782 Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
AIN457F
NOVARTIS PHARMA AG
- Phase 3 EUCTR2016-003761-26-IT Belgium;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
AMG-407
Amgen Inc.
2021 Phase 3 EUCTR2019-002788-88-NL Austria;Belgium;France;Italy;Netherlands;
2021 Phase 3 EUCTR2019-002788-88-FR Austria;Belgium;France;Netherlands;
- Phase 3 EUCTR2019-002788-88-PL Austria;Belgium;France;Italy;Netherlands;Poland;
- Phase 3 EUCTR2019-002788-88-BE Austria;Belgium;Netherlands;
- Phase 3 EUCTR2019-002788-88-AT Austria;Belgium;France;Italy;Netherlands;
AMG407
AMGEN INC.
2021 Phase 3 EUCTR2019-002788-88-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;
Amgen Inc.
2021 Phase 3 EUCTR2019-002788-88-NL Austria;Belgium;France;Italy;Netherlands;
2021 Phase 3 EUCTR2019-002788-88-FR Austria;Belgium;France;Netherlands;
- Phase 3 EUCTR2019-002788-88-PL Austria;Belgium;France;Italy;Netherlands;Poland;
- Phase 3 EUCTR2019-002788-88-BE Austria;Belgium;Netherlands;
- Phase 3 EUCTR2019-002788-88-AT Austria;Belgium;France;Italy;Netherlands;
APD421
Pfizer Inc
2012 Phase 2;Phase 3 EUCTR2011-004915-22-SK Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
2018 Phase 2;Phase 3 EUCTR2011-004915-22-BE Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2011-004915-22-SE Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc.
2020 Phase 3 EUCTR2017-002018-29-SK Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc. 235 East 42nd Street, New York, New York 10017
2022 Phase 3 EUCTR2017-002018-29-HU Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-NL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-DE Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2017-002018-29-PL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-SE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-BE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Abalimumab bio-originatore
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
Abatacept
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 3 EUCTR2016-000312-15-FR France;
Assistance Publique - Hôpitaux de Paris
2017 Phase 3 NCT02840175 France;
Bristol-Myers Squibb
2013 Phase 3 NCT01844518 Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 NCT01835470 Japan;
Bristol-Myers Squibb K.K.
2013 Phase 3 JPRN-JapicCTI-132119 Japan;
Yokohama City University Hospital Department of Pediatrics
2016 - JPRN-UMIN000024178 Japan;
Abatacept Injection
Duke University
2019 Phase 3 NCT03841357 United States;
Actemra
F. Hoffmann-La Roche Limited
2008 - EUCTR2007-000872-18-SK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-ES Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-DK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
Actemra, MRA
F. Hoffmann-La Roche Limited
- Phase 3 EUCTR2007-000872-18-NO Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
Adalimumab
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 3 EUCTR2016-000312-15-FR France;
AbbVie
2008 - NCT00783510 Australia;Austria;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Portugal;Puerto Rico;Slovakia;Spain;Sweden;United States;
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00775437 Czech Republic;Denmark;France;Germany;Puerto Rico;Slovakia;Sweden;United States;
Assistance Publique - Hôpitaux de Paris
2017 Phase 3 NCT02840175 France;
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Eli Lilly and Company
2021 Phase 3 NCT04527380 Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom;
2019 Phase 3 NCT04088409 France;Germany;Italy;Spain;United Kingdom;
F.I. Proctor Foundation, University of California San Francisco
2019 Phase 4 EUCTR2019-000412-29-GB Australia;United Kingdom;United States;
Nisha Acharya
2020 Phase 4 NCT03816397 Australia;United Kingdom;United States;
Adalimumab (20mg)
University Hospitals Bristol NHS Foundation Trust
2011 Phase 2 EUCTR2010-021141-41-GB United Kingdom;
Adalimumab (40mg)
University Hospitals Bristol NHS Foundation Trust
2011 Phase 2 EUCTR2010-021141-41-GB United Kingdom;
Adalimumab biosimilare
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
Alfacalcidol 2 micrograms/ml
Belfast Health and Social Care Trust, Musgrave Park Hospital
2006 Phase 4 EUCTR2005-003129-23-GB United Kingdom;
Ambirix
Public Health Service Amsterdam
2009 - EUCTR2008-003280-40-NL Netherlands;
Anakinra
ISTITUTO GIANNINA GASLINI
2005 - EUCTR2005-004008-36-IT Italy;
Institut National de la Santé Et de la Recherche Médicale, France
2006 Phase 2/Phase 3 NCT00339157 France;
Swedish Orphan Biovitrum
2019 - NCT03932344 Italy;
Anakinra / kineret
University Medical Center Utrecht
2016 Phase 4 EUCTR2015-004393-16-NL Netherlands;
Anti-TNF
University of Sao Paulo
2008 Phase 4 NCT02196480 Brazil;
Anti-pandemic H1N1 influenza vaccine
University of Sao Paulo
2010 Phase 4 NCT01151644 Brazil;
Anti-tumor necrosis factor alpha monoclonal antibody
Assistance Publique - Hôpitaux de Paris
2011 Phase 2/Phase 3 NCT01385826 France;
Antivirale ad uso diretto
Swedish Orphan Biovitrum AG
- Phase 2;Phase 3 EUCTR2021-001577-24-IT Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Apremilast
AMGEN INC.
2021 Phase 3 EUCTR2019-002788-88-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;
Amgen Inc.
2021 Phase 3 EUCTR2019-002788-88-NL Austria;Belgium;France;Italy;Netherlands;
2021 Phase 3 EUCTR2019-002788-88-FR Austria;Belgium;France;Netherlands;
- Phase 3 EUCTR2019-002788-88-PL Austria;Belgium;France;Italy;Netherlands;Poland;
- Phase 3 EUCTR2019-002788-88-BE Austria;Belgium;Netherlands;
- Phase 3 EUCTR2019-002788-88-AT Austria;Belgium;France;Italy;Netherlands;
BMS-188667
Bristol-Myers Squibb International Corporation
2013 Phase 3 EUCTR2012-003195-39-IT Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-ES Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-DE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-BE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- Phase 3 EUCTR2012-003195-39-FR Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- - EUCTR2016-000940-32-Outside-EU/EEA Japan;
- - EUCTR2012-003195-39-Outside-EU/EEA Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
Baricitinib
Eli Lilly and Company
2020 Phase 3 NCT04088396 Argentina;Austria;Belgium;Brazil;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 NCT04088409 France;Germany;Italy;Spain;United Kingdom;
2019 Phase 3 NCT03773965 Argentina;Australia;Austria;Belgium;Brazil;China;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2018 Phase 3 NCT03773978 Argentina;Australia;Austria;Belgium;Brazil;China;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Biological DMARDs
Hoffmann-La Roche
2000 - NCT02784808 -
Biosimilar Etanercept
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
Biosimilar adalimumab
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
Blood sample
University Hospital, Montpellier
2014 - NCT02067962 -
Bof-, Mazelen-, Rubellavaccin, poeder voor injectievloeistof
University Medical Center Utrecht
2008 - EUCTR2007-001861-14-NL Netherlands;
CCP-690-550-10
PFIZER INC
2020 Phase 3 EUCTR2017-002018-29-IT Argentina;Belgium;Brazil;Canada;Chile;China;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
CNTO 148 (Golimumab)
Janssen Research & Development, LLC
2010 Phase 3 NCT01230827 Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;United States;
CNTO148
Janssen Biologics B.V.
2011 Phase 3 EUCTR2009-015019-42-BE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2011 - EUCTR2009-015019-42-DE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
2010 - EUCTR2009-015019-42-LT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-FI Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-AT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
- - EUCTR2009-015019-42-Outside-EU/EEA Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA
NOVARTIS PHARMA AG
- Phase 3 EUCTR2016-003761-26-IT Belgium;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE
NOVARTIS PHARMA AG
2019 Phase 3 EUCTR2018-002521-30-IT Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
CP-690, 550-10
PFIZER INC
2020 Phase 3 EUCTR2017-002018-29-IT Argentina;Belgium;Brazil;Canada;Chile;China;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
CP-690,550
PFIZER INC.
2013 - EUCTR2011-004915-22-IT Argentina;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;
Pfizer
2013 Phase 1 NCT01513902 Germany;Hungary;Poland;Slovakia;United States;
CP-690,550 (tofacitinib)
Pfizer
2016 Phase 3 NCT02592434 Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
CP-690,550-10
PFIZER INC.
2012 - EUCTR2011-004914-40-IT Argentina;Hungary;Italy;Mexico;Poland;Russian Federation;
Pfizer Inc
2012 Phase 2;Phase 3 EUCTR2011-004915-22-SK Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2012 Phase 1 EUCTR2011-004914-40-HU Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
2012 - EUCTR2011-004914-40-SK Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
2012 - EUCTR2011-004914-40-PL Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
2019 Phase 3 EUCTR2015-001438-46-PL Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2015-001438-46-ES Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2015-001438-46-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2015-001438-46-BE Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2011-004915-22-BE Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-004915-22-PL Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-004915-22-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-004915-22-HU Czech Republic;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Slovakia;
- Phase 2;Phase 3 EUCTR2011-004915-22-SE Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2011-004915-22-NL Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc.
2020 Phase 3 EUCTR2017-002018-29-SK Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2015-001438-46-GB Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2011-004915-22-GB Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc. 235 East 42nd Street, New York, New York 10017
2022 Phase 3 EUCTR2017-002018-29-HU Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-NL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-DE Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2017-002018-29-PL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-SE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-BE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
CP-690-550-10 (DMID D1600180)
Pfizer Inc
2012 Phase 2;Phase 3 EUCTR2011-004915-22-SK Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
2018 Phase 2;Phase 3 EUCTR2011-004915-22-BE Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2011-004915-22-SE Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc.
2020 Phase 3 EUCTR2017-002018-29-SK Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc. 235 East 42nd Street, New York, New York 10017
2022 Phase 3 EUCTR2017-002018-29-HU Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-NL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-DE Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2017-002018-29-PL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-SE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-BE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
CSs
Hoffmann-La Roche
2018 Phase 4 NCT03301883 China;
Canakinumab
NOVARTIS FARMA
2009 - EUCTR2008-008008-42-IT Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-IT Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-IT Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
Novartis Farmacéutica S.A.
2009 Phase 3 EUCTR2008-005476-27-ES Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-ES Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-ES Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
Novartis Pharma K.K.
2015 Phase 3 JPRN-JapicCTI-152865 -
Novartis Pharma Services AG
2010 - EUCTR2008-008008-42-GR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005479-82-GR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005476-27-GR Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005476-27-GB Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005479-82-FR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005479-82-BE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005476-27-FR Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-SE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Russian Federation;Spain;Swaziland;Sweden;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-GB Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-FR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-DK Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-DE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-005479-82-SE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-HU Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-GB Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-DK Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-DE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-AT Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-SE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-HU Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-DK Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-DE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-BE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-008008-42-NO Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-005479-82-NO Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-005476-27-NO Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
Novartis Pharmaceuticals
2015 Phase 3 NCT02396212 Japan;
2014 Phase 3 NCT02334748 France;
2013 Phase 3 NCT01676948 Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 Phase 3 NCT00891046 Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 Phase 3 NCT00889863 Argentina;Belgium;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;South Africa;Spain;Sweden;Switzerland;Turkey;United States;
2009 Phase 3 NCT00886769 Argentina;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Celebrex
Pfizer Inc
- - EUCTR2014-003737-26-Outside-EU/EEA Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Ukraine;United States;
Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009 Phase 4 NCT00807846 Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Switzerland;Ukraine;United States;
2009 - NCT00688545 United States;
Certolizumab Pegol (CZP)
UCB BIOSCIENCES GmbH
2012 Phase 3 NCT01550003 Argentina;Brazil;Canada;Chile;Mexico;Russian Federation;United States;
Cervarix suspensie voor injectie
University Medical Center Utrecht
2009 - EUCTR2008-008169-36-NL Netherlands;
Collection of samples
Institut National de la Santé Et de la Recherche Médicale, France
2021 - NCT04902807 -
Combination of DMARDs
Helsinki University Central Hospital
2003 Phase 3 NCT01015547 Finland;
Corticosteroids
Hoffmann-La Roche
2008 Phase 3 NCT00642460 Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
Cyclosporine A
St. Franziskus Hospital
1991 - NCT00404482 Germany;
Daclizumab
National Eye Institute (NEI)
2005 Phase 2 NCT00130637 United States;
Dexmedetomidine
University of Oulu
2017 Phase 4 NCT03069638 Finland;
Diethyl-[6-(4-hydroxycarbamoyl- phenyl carbamoyloxymethyl)-naphthalen-2-yl methyl]-ammonium chloride
Italfarmaco S.p.A.
2011 - EUCTR2011-003341-18-CZ Czech Republic;
Double-Blind Adalimumab
Abbott
2002 Phase 3 NCT00048542 Belgium;Czech Republic;France;Germany;Italy;Slovakia;Spain;United States;
ENBREL 25 mg/ml polvo y disolvente para solución inyectable para uso pediátrico
PFIZER, S.L.U.
2011 - EUCTR2010-023802-10-ES Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States
2012 Phase 3 EUCTR2010-023802-10-NL Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
ENBREL 50 mg solución inyectable en jeringas precargadas
PFIZER, S.L.U.
2011 - EUCTR2010-023802-10-ES Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States
2012 Phase 3 EUCTR2010-023802-10-NL Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
ENBREL*BB SC 4FL 25MG 1ML+4SIR
Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
2010 - EUCTR2009-012520-84-IT Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
EU/1/03/256/001
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
EU/1/07/389/001
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
EU/1/99/126/001
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
EX VIVO CULTURED HUMAN MESENCHYMAL STEM CELLS
University Medical Center Utrecht
2014 - EUCTR2012-002067-10-NL Netherlands;
Emapalumab
Novimmune SA
2017 Phase 2 EUCTR2016-004223-23-ES France;Germany;Italy;Netherlands;Spain;United Kingdom;
Swedish Orphan Biovitrum
2018 Phase 2 NCT03311854 France;Italy;Netherlands;Spain;United Kingdom;United States;
Swedish Orphan Biovitrum AG
- Phase 2;Phase 3 EUCTR2021-001577-24-IT Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Swedish Orphan Biovitrum AG (Sobi AG)
2021 Phase 2;Phase 3 EUCTR2021-001577-24-PL Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2021-001577-24-ES Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2021-001577-24-SE Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2021-001577-24-FR Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2021-001577-24-CZ Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Enbrel
IRCCS Istituto Giannina Gaslini
2019 Phase 3 EUCTR2018-001931-27-IT Italy;
PFIZER INC.
2012 - EUCTR2010-023802-10-IT Australia;Belgium;Colombia;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Russian Federation;Slovakia;Slovenia;Spain;
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
Wyeth Kabushiki Kaisha (Wyeth K.K.)
- - EUCTR2014-004103-73-Outside-EU/EEA Japan;
Wyeth Pharmaceuticals Inc, (a Pfizer Company) 500 Arcola Road, Collegeville, PA 19426 USA
2010 - EUCTR2009-012520-84-CZ Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 Phase 3 EUCTR2009-012520-84-BE Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovakia;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-SI Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-LV Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-LT Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-DE Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
- - EUCTR2009-012520-84-Outside-EU/EEA Australia;Colombia;Mexico;Russian Federation;Serbia;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
2009 Phase 3 EUCTR2009-012520-84-SK Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company, Philadelphia, PA-19101, USA
2010 - EUCTR2009-012520-84-DK Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-SE Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
2010 Phase 3 EUCTR2009-012520-84-GR Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
2010 - EUCTR2009-012520-84-NL Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
2009 Phase 3 EUCTR2009-012520-84-ES Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-HU Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-FR Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
Enbrel (Etanercept)
Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320
- - EUCTR2012-001171-37-Outside-EU/EEA Canada;United States;
- - EUCTR2012-001145-40-Outside-EU/EEA Canada;United States;
Enbrel®
Asklepios-Klinik Sankt Augustin
2007 - EUCTR2007-000255-34-DE Germany;
Pfizer Inc.235 East 42nd Street, New York, NY 10017
2012 Phase 3 EUCTR2010-023802-10-NO Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-SK Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-SI Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-LV Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-LT Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-HU Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-FR Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-DE Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-CZ Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-BE Australia;Belgium;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
- Phase 3 EUCTR2010-023802-10-PL Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
- - EUCTR2010-023802-10-Outside-EU/EEA Australia;Colombia;Mexico;Russian Federation;Serbia;
Samsung Bioepis Co., Ltd.
2013 Phase 3 EUCTR2012-005026-30-HU Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-PL Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-CZ Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-BG Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
Entecavir
Seoul National University Hospital
2012 Phase 3 NCT01694264 Korea, Republic of;
Esomeprazole
AstraZeneca
2011 Phase 1 NCT01358383 United States;
Etanercept
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 3 EUCTR2016-000312-15-FR France;
Assistance Publique - Hôpitaux de Paris
2017 Phase 3 NCT02840175 France;
Erasmus Medical Center
2011 Phase 4 NCT01287715 Netherlands;
Pfizer
2011 Phase 3 NCT01421069 Australia;Belgium;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2009 Phase 3 NCT00962741 Argentina;Australia;Belgium;Brazil;Colombia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;Sweden;Taiwan;
Wyeth Pharmaceuticals Inc, (a Pfizer Company) 500 Arcola Road, Collegeville, PA 19426 USA
2010 - EUCTR2009-012520-84-CZ Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 Phase 3 EUCTR2009-012520-84-BE Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovakia;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-SI Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-LV Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-LT Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-DE Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
- - EUCTR2009-012520-84-Outside-EU/EEA Australia;Colombia;Mexico;Russian Federation;Serbia;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
2009 Phase 3 EUCTR2009-012520-84-SK Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company, Philadelphia, PA-19101, USA
2010 - EUCTR2009-012520-84-DK Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-SE Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
2010 Phase 3 EUCTR2009-012520-84-GR Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
2010 - EUCTR2009-012520-84-NL Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
2010 - EUCTR2009-012520-84-IT Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
2009 Phase 3 EUCTR2009-012520-84-ES Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-HU Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-FR Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
Wyeth is now a wholly owned subsidiary of Pfizer
2003 - NCT00195377 Spain;
Etanercept (genetical recombination)
Pfizer
2009 - NCT01145352 Japan;
Etanercept Optimal dosing
Duke University
2023 Phase 1 NCT04585711 United States;
Etanercept biosimilare
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
Folic/folinic acid
University of British Columbia
2019 - NCT04169828 Canada;
Fully human anti-interferon gamma monoclonal antibody
Novimmune SA
- Phase 2 EUCTR2016-004223-23-FR Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
Genakumab
GeneScience Pharmaceuticals Co., Ltd.
2019 Phase 1 NCT04337437 China;
Genicular nerve block
Sohag University
2020 Phase 4 NCT04687930 Egypt;
Genotropin
Ludwig-Maximilians - University of Munich
1996 Phase 3 NCT00420251 Germany;
Pfizer Inc
- - EUCTR2014-004105-32-Outside-EU/EEA France;
Pharmacia & Upjohn S.A.
- - EUCTR2014-004104-30-Outside-EU/EEA France;
Givinostat
ITALFARMACO
2010 - EUCTR2010-019094-15-IT Czech Republic;Italy;Slovenia;Spain;
Italfarmaco
2011 - NCT01557452 Czech Republic;
2010 Phase 2 NCT01261624 Belgium;Czech Republic;Italy;Romania;Serbia;Slovenia;Spain;
Givinostat (hydrochloride-monohydrate)
Italfarmaco S.p.A.
2011 - EUCTR2011-003341-18-CZ Czech Republic;
2010 Phase 2 EUCTR2010-019094-15-BE Belgium;Czech Republic;Italy;Slovenia;Spain;
2010 - EUCTR2010-019094-15-SI Czech Republic;Italy;Slovenia;Spain;
2010 - EUCTR2010-019094-15-ES Czech Republic;Italy;Slovenia;Spain;
2010 - EUCTR2010-019094-15-CZ Czech Republic;Italy;Slovenia;Spain;
Golimumab
Janssen Research & Development, LLC
2014 Phase 3 NCT02277444 Argentina;Brazil;Canada;Chile;Israel;Mexico;Puerto Rico;Russian Federation;South Africa;United States;
Medical University of Graz
2010 - NCT04200833 -
Golimumab Liquid in prefilled syringe
Janssen Biologics B.V.
2011 Phase 3 EUCTR2009-015019-42-BE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2011 - EUCTR2009-015019-42-DE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
2010 - EUCTR2009-015019-42-LT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-FI Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-AT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
- - EUCTR2009-015019-42-Outside-EU/EEA Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
HUMIRA
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 3 EUCTR2016-000312-15-FR France;
Heparin
Shanghai Children's Medical Center
2015 - ChiCTR-OOC-15006228 China;
Human anti-TNF-alpha monoclonal antibody
Janssen Biologics B.V.
2011 Phase 3 EUCTR2009-015019-42-BE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2011 - EUCTR2009-015019-42-DE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
2010 - EUCTR2009-015019-42-LT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-FI Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-AT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
- - EUCTR2009-015019-42-Outside-EU/EEA Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
Humira
AbbVie Deutschland GmbH & Co. KG
2010 - EUCTR2009-013091-40-SE Czech Republic;France;Germany;Sweden;
2010 - EUCTR2009-013091-40-CZ Czech Republic;France;Germany;Sweden;
Abbott GmbH & Co. KG
2010 Phase 3 EUCTR2009-013091-40-SK Czech Republic;Denmark;France;Germany;Slovakia;Sweden;
2010 Phase 3 EUCTR2009-013091-40-FR Czech Republic;Denmark;France;Germany;Slovakia;Sweden;
2010 Phase 3 EUCTR2009-013091-40-DK Czech Republic;Denmark;France;Germany;Sweden;
2010 - EUCTR2009-013091-40-DE Czech Republic;France;Germany;Sweden;
- - EUCTR2009-013091-40-Outside-EU/EEA -
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-IT European Union;France;Germany;Italy;United Kingdom;
Eli Lilly and Company
2021 Phase 3 EUCTR2018-000681-10-CZ Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-000119-10-DE France;Germany;Italy;Spain;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-GB Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DK Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DE Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-GB France;Germany;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-FR France;Germany;United Kingdom;
- Phase 3 EUCTR2018-000681-10-NL Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-FR Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-BE Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
F.I. Proctor Foundation, University of California San Francisco
2019 Phase 4 EUCTR2019-000412-29-GB Australia;United Kingdom;United States;
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
Humira®
Samsung Bioepis Co., Ltd.
2014 Phase 3 EUCTR2013-005013-13-BG Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-PL Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-LT Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
IL-2
The First Hospital of Jilin University
2020 - NCT04397107 China;
IL-6 receptor inhibitor, recombinant humanized monoclonal antibody
F. Hoffmann-La Roche Ltd
2015 Phase 1 EUCTR2015-000435-33-PL Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-HU Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-GB Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-DE Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-BE Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011593-15-GB Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 Phase 3 EUCTR2009-011593-15-BE Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 1 EUCTR2015-000435-33-FR Argentina;Belgium;Canada;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd.
2012 Phase 4 EUCTR2012-000444-10-SE Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-GB Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-ES Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-DE Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2007-000872-18-GB Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-DE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-CZ Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-BE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 4 EUCTR2012-000444-10-NO Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
Roche Farma S.A en nombre de F. Hoffmann-La Roche Ltd
2015 Phase 1 EUCTR2015-000435-33-ES Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
ITF2357
ITALFARMACO
2006 - EUCTR2006-000089-35-IT Italy;
Italfarmaco
2006 Phase 2 NCT00570661 Former Serbia and Montenegro;Serbia;
Italfarmaco S.p.A.
2011 - EUCTR2011-003341-18-CZ Czech Republic;
2010 Phase 2 EUCTR2010-019094-15-BE Belgium;Czech Republic;Italy;Slovenia;Spain;
2010 - EUCTR2010-019094-15-SI Czech Republic;Italy;Slovenia;Spain;
2010 - EUCTR2010-019094-15-ES Czech Republic;Italy;Slovenia;Spain;
2010 - EUCTR2010-019094-15-CZ Czech Republic;Italy;Slovenia;Spain;
Ilaris
Asklepios Klink Sankt Augustin
2020 Phase 4 EUCTR2018-004284-30-DE Germany;
Novartis Farmacéutica, S.A.
2014 Phase 3;Phase 4 EUCTR2013-004867-29-ES Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
Novartis Pharma Services AG
2009 - EUCTR2008-008008-42-BE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
In double-blind phase: treatment with tofacitinib
Pfizer
2018 Phase 3 NCT03000439 Argentina;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
In open-label phase: treatment with tofacitinib
Pfizer
2018 Phase 3 NCT03000439 Argentina;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
Infliximab plus methotrexate
Helsinki University Central Hospital
2003 Phase 3 NCT01015547 Finland;
Influenza vaccine, Immune function
University of Pecs
2018 Early Phase 1 NCT03833271 Hungary;
Intra-articular steroid injection
Sohag University
2020 Phase 4 NCT04687930 Egypt;
Ixekizumab
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Eli Lilly and Company
2021 Phase 3 NCT04527380 Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom;
KINERET*SC 7SIR 100MG 0,67ML
ISTITUTO GIANNINA GASLINI
2005 - EUCTR2005-004008-36-IT Italy;
Kineret® or anakinra
University Medical Center Utrecht
2016 Phase 4 EUCTR2015-004393-16-NL Netherlands;
L01BA01
ISTITUTO GIANNINA GASLINI-PRINTO
2005 - EUCTR2005-001086-34-DK Denmark;Italy;Spain;
Istituto Giannina Gaslini-PRINTO
2005 - EUCTR2005-001086-34-ES Denmark;Italy;Spain;
L04AB04
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-IT European Union;France;Germany;Italy;United Kingdom;
Eli Lilly and Company
2020 Phase 3 EUCTR2019-000119-10-DE France;Germany;Italy;Spain;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-GB France;Germany;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-FR France;Germany;United Kingdom;
LY2439821
Eli Lilly and Company
2021 Phase 3 EUCTR2018-000681-10-CZ Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-GB Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DK Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DE Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-NL Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-FR Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-BE Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
LY3009104
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 3 EUCTR2019-000119-10-IT European Union;France;Germany;Italy;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-IT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004495-60-IT Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-IT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Eli Lilly and Company
2020 Phase 3 EUCTR2019-000119-10-DE France;Germany;Italy;Spain;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-GB France;Germany;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-FR France;Germany;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-PL Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-GB Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-FR Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-DK Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-DE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-CZ Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-BE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-AT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-PL Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-GB Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-FR Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-DK Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-DE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-CZ Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-BE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
- Phase 3 EUCTR2017-004471-31-AT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Lilly S.A.
2019 Phase 3 EUCTR2017-004518-24-ES Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-ES Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Lederspan
Oslo University Hospital
2020 Phase 4 EUCTR2019-000889-38-NO Norway;
Leflunomide
Mashhad University of Medical Sciences
2013 Phase 4 NCT02024334 Iran, Islamic Republic of;
Lidocaine
Sohag University
2021 Phase 3 NCT04775225 Egypt;
METHOTREXATE DISODIUM
University of Munster
2008 Phase 4 EUCTR2006-006812-31-DE Germany;Netherlands;
university medical centre utrecht
2007 Phase 4 EUCTR2006-006812-31-NL Germany;Netherlands;
METHOTREXATE*25CPR 2,
ISTITUTO GIANNINA GASLINI
2008 - EUCTR2008-006741-70-IT Italy;
MRA
F. Hoffmann-La Roche Limited
2008 - EUCTR2007-000872-18-SK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-DK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
MRA (Actemra)
F. Hoffmann-La Roche Ltd.
2008 Phase 3 EUCTR2007-000872-18-GR Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
MRA (tocilizumab)
Chugai Pharmaceutical Co., Ltd.
- Phase 3 JPRN-JapicCTI-050017 -
MRA(Tocilizumab)
Chugai Pharmaceutical
2005 Phase 3 NCT00144625 -
2004 Phase 3 NCT00144664 -
2004 Phase 3 NCT00144612 -
2004 Phase 3 NCT00144599 -
MRA, Actemra
F. Hoffmann-La Roche Limited
2008 - EUCTR2007-000872-18-SE Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-NL Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
MSB11022
Fresenius Kabi SwissBioSim GmbH
2019 Phase 1 NCT04018599 United States;
MTX
Hoffmann-La Roche
2018 Phase 4 NCT03301883 China;
Measles, Mumps, Rubella vaccination
N.M. Wulffraat
2008 Phase 4 NCT00731965 Netherlands;
Methotrexate
AbbVie
2008 - NCT00783510 Australia;Austria;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Portugal;Puerto Rico;Slovakia;Spain;Sweden;United States;
Hoffmann-La Roche
2008 Phase 3 NCT00642460 Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
ISTITUTO GIANNINA GASLINI
2005 - EUCTR2005-001086-34-IT Denmark;Italy;Spain;
ISTITUTO GIANNINA GASLINI-PRINTO
2005 - EUCTR2005-001086-34-DK Denmark;Italy;Spain;
Institute of Child Health
2006 - NCT00415935 United Kingdom;
Istituto Giannina Gaslini-PRINTO
2005 - EUCTR2005-001086-34-ES Denmark;Italy;Spain;
Janssen Research & Development, LLC
2014 Phase 3 NCT02277444 Argentina;Brazil;Canada;Chile;Israel;Mexico;Puerto Rico;Russian Federation;South Africa;United States;
2010 Phase 3 NCT01230827 Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;United States;
Leiden University
- Phase 4 EUCTR2018-001571-21-NL Netherlands;
University of British Columbia
2019 - NCT04169828 Canada;
Methotrexate - etanercept - prednisolone arm
Seattle Children's Hospital
2007 Phase 4 NCT00443430 United States;
Methotrexate alone
Helsinki University Central Hospital
2003 Phase 3 NCT01015547 Finland;
Methotrexate prefilled pen
medac GmbH
2014 Early Phase 1 NCT02052167 United States;
Metoject
University of Munster
2008 Phase 4 EUCTR2006-006812-31-DE Germany;Netherlands;
university medical centre utrecht
2007 Phase 4 EUCTR2006-006812-31-NL Germany;Netherlands;
Metotrexato
Istituto Giannina Gaslini-PRINTO
2005 - EUCTR2005-001086-34-ES Denmark;Italy;Spain;
NAPROXEN SODIUM
Pfizer Inc
- - EUCTR2014-003737-26-Outside-EU/EEA Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Ukraine;United States;
NI-0501
Novimmune SA
2018 Phase 2 EUCTR2016-004223-23-NL Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004223-23-IT France;Germany;Italy;Netherlands;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004223-23-ES France;Germany;Italy;Netherlands;Spain;United Kingdom;
- Phase 2 EUCTR2016-004223-23-FR Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
Swedish Orphan Biovitrum AG
2017 Phase 2 EUCTR2016-004223-23-GB Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2021-001577-24-IT Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Swedish Orphan Biovitrum AG (Sobi AG)
2021 Phase 2;Phase 3 EUCTR2021-001577-24-PL Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2021-001577-24-ES Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2021-001577-24-SE Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2021-001577-24-FR Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2021-001577-24-CZ Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
NSAIDs
Hoffmann-La Roche
2018 Phase 4 NCT03301883 China;
Naproxen
AstraZeneca
2011 Phase 1 NCT01358383 United States;
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009 Phase 4 NCT00807846 Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Switzerland;Ukraine;United States;
Nicotinamide
UMC Utrecht
- Phase 1;Phase 2 EUCTR2016-003643-10-NL Netherlands;
Non-Biologic DMARDs
Hoffmann-La Roche
2000 - NCT02784808 -
Non-steroidal anti-inflammatory drugs (NSAIDs)
Hoffmann-La Roche
2008 Phase 3 NCT00642460 Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
Norditropin SimpleXx 5mg/1.5ml
Royal Hospital For Sick Children, Yorkhill Division
2004 - EUCTR2004-004153-25-GB United Kingdom;
NsNSAIDs
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009 - NCT00688545 United States;
OLE BSA Adalimumab +/- MTX
Abbott
2002 Phase 3 NCT00048542 Belgium;Czech Republic;France;Germany;Italy;Slovakia;Spain;United States;
OLE FD Adalimumab +/- MTX
Abbott
2002 Phase 3 NCT00048542 Belgium;Czech Republic;France;Germany;Italy;Slovakia;Spain;United States;
OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA
AMGEN INC.
2021 Phase 3 EUCTR2019-002788-88-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;
OTEZLA - 30 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/ALU) - 56 COMPRESSE
AMGEN INC.
2021 Phase 3 EUCTR2019-002788-88-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;
Olumiant
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 3 EUCTR2019-000119-10-IT European Union;France;Germany;Italy;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-IT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Eli Lilly and Company
2020 Phase 3 EUCTR2019-000119-10-DE France;Germany;Italy;Spain;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-GB France;Germany;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-FR France;Germany;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-PL Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-GB Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-FR Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-DK Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-DE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-CZ Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-BE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-AT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004495-60-PL Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004495-60-GB Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004495-60-FR Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004495-60-DK Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-PL Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-GB Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-FR Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-DK Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-DE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-CZ Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-BE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
- Phase 3 EUCTR2017-004495-60-DE Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
- Phase 3 EUCTR2017-004495-60-CZ Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
- Phase 3 EUCTR2017-004495-60-BE Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
- Phase 3 EUCTR2017-004495-60-AT Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
- Phase 3 EUCTR2017-004471-31-AT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Lilly S.A.
2019 Phase 3 EUCTR2017-004518-24-ES Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-ES Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Oluminant
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 3 EUCTR2017-004518-24-IT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Ondansetron
University of British Columbia
2019 - NCT04169828 Canada;
One Alpha Drops
Belfast Health and Social Care Trust, Musgrave Park Hospital
2006 Phase 4 EUCTR2005-003129-23-GB United Kingdom;
One-Alpha drops
Belfast Health and Social Care Trust, Musgrave Park Hospital
2006 Phase 4 EUCTR2005-003129-23-GB United Kingdom;
Orencia
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
Originator adalimumab
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
Otezla
Amgen Inc.
2021 Phase 3 EUCTR2019-002788-88-NL Austria;Belgium;France;Italy;Netherlands;
2021 Phase 3 EUCTR2019-002788-88-FR Austria;Belgium;France;Netherlands;
- Phase 3 EUCTR2019-002788-88-PL Austria;Belgium;France;Italy;Netherlands;Poland;
- Phase 3 EUCTR2019-002788-88-BE Austria;Belgium;Netherlands;
- Phase 3 EUCTR2019-002788-88-AT Austria;Belgium;France;Italy;Netherlands;
Pneumo23
Institut National de la Santé Et de la Recherche Médicale, France
2006 Phase 2/Phase 3 NCT00339157 France;
Profilassi per Herpes Zoster
Swedish Orphan Biovitrum AG
- Phase 2;Phase 3 EUCTR2021-001577-24-IT Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Quadrivalent HPV vaccine
The University of New South Wales
2007 Phase 3 NCT02263703 Australia;
RIL-1RA
University Medical Center Utrecht
2016 Phase 4 EUCTR2015-004393-16-NL Netherlands;
RO4877533
Roche Pharma AG
2011 - EUCTR2011-001097-25-DE Germany;
RO4877533 (TCZ)
F. Hoffmann-La Roche Limited
2008 - EUCTR2007-000872-18-SK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-SE Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-NL Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-ES Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-DK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2007-000872-18-NO Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
F. Hoffmann-La Roche Ltd.
2008 Phase 3 EUCTR2007-000872-18-GR Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2007-000872-18-GB Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-DE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-CZ Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-BE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
ROCHE
2008 - EUCTR2007-000872-18-IT Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
ROACTEMRA 20 mg/ml, concentrado para solución para perfusión
F. Hoffmann-La Roche Ltd
2009 Phase 3 EUCTR2009-011593-15-ES Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
RVG 104433
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
RVG 28636
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
Recombinant antihumanized anti-human monoclonal antibody directed against the IL-6R
F. Hoffmann-La Roche Ltd
2013 Phase 1 EUCTR2012-003490-26-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2012-003490-26-Outside-EU/EEA Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class
Novartis Farmacéutica S.A.
2009 Phase 3 EUCTR2008-005476-27-ES Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-ES Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-ES Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
Novartis Pharma Services AG
2010 - EUCTR2008-008008-42-GR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005479-82-GR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005476-27-GR Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005476-27-GB Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005479-82-FR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005479-82-BE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005476-27-FR Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-SE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Russian Federation;Spain;Swaziland;Sweden;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-GB Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-FR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-DK Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-DE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-005479-82-SE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-HU Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-GB Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-DK Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-DE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-AT Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-SE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-HU Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-DK Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-DE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-BE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-008008-42-NO Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-005479-82-NO Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-005476-27-NO Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
Recombinant humanized anti-human monoclonal antibody directed against the IL-6R
F. Hoffmann-La Roche Ltd.
2013 Phase 1 EUCTR2012-003486-18-PL Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2012-003486-18-Outside-EU/EEA Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
Reumaflex
IRCCS Istituto Giannina Gaslini
2019 Phase 3 EUCTR2018-001931-27-IT Italy;
Rilonacept
Montefiore Medical Center
2008 Phase 2 NCT00534495 United States;
Rilonacept (IL-1 Trap)
Regeneron Pharmaceuticals
2005 Phase 1 NCT01803321 United States;
Ro 487-7533/F01
F. Hoffmann-La Roche Ltd
2010 - EUCTR2009-011593-15-NL Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011593-15-GB Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 Phase 3 EUCTR2009-011593-15-BE Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 - EUCTR2009-011593-15-FR Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-011593-15-DE Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
Ro 487-7533/F10
University Hospitals Bristol NHS Foundation Trust
2015 Phase 2 EUCTR2015-001323-23-GB United Kingdom;
Ro 487-7533/F10-04
F. Hoffmann-La Roche Ltd
2014 Phase 1 EUCTR2013-005212-98-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 1 EUCTR2013-005212-98-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 1 EUCTR2013-005212-98-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
- Phase 1 EUCTR2013-005212-98-FR Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2012-003490-26-Outside-EU/EEA Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd.
2013 Phase 1 EUCTR2012-003486-18-PL Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2012-003486-18-Outside-EU/EEA Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
Roche Farma S.A. en nombre de F. Hoffmann-La Roche Ltd
2014 - EUCTR2013-005212-98-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States;
Ro-Actemra
Roche Pharma AG
2011 - EUCTR2011-001097-25-DE Germany;
RoActemra
F. HOFFMANN - LA ROCHE LTD.
2013 Phase 4 EUCTR2012-000444-10-IT Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
F. Hoffmann-La Roche Ltd
2014 Phase 1 EUCTR2013-005212-98-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 1 EUCTR2013-005212-98-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2010 - EUCTR2009-011593-15-NL Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011593-15-GB Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 Phase 3 EUCTR2009-011593-15-BE Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 - EUCTR2009-011593-15-IT Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-011593-15-FR Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-011593-15-DE Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd.
2013 Phase 1 EUCTR2012-003486-18-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2012 Phase 4 EUCTR2012-000444-10-SE Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-GB Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-ES Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-DE Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2007-000872-18-GB Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-DE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-CZ Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-BE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 4 EUCTR2012-000444-10-NO Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
Roche Farma S.A. en nombre de F. Hoffmann-La Roche Ltd
2014 - EUCTR2013-005212-98-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States;
Roche Pharma AG
2011 - EUCTR2011-001097-25-DE Germany;
University Hospitals Bristol NHS Foundation Trust
2015 Phase 2 EUCTR2015-001323-23-GB United Kingdom;
RoActemra/Actemra (tocilizumab)
Hoffmann-La Roche
2012 Phase 3 NCT01575769 Poland;Russian Federation;
SAR153191 (REGN88)
sanofi-aventis recherche & développement
2021 Phase 2 EUCTR2015-004000-35-IE Argentina;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2021 Phase 2 EUCTR2015-004000-35-BG Argentina;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2015-004000-35-PL Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2015-004000-35-NL Argentina;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2015-004000-35-GB Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2015-004000-35-DE Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2015-003999-79-DE Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004000-35-IT Argentina;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004000-35-FI Argentina;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004000-35-ES Argentina;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004000-35-EE Argentina;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003999-79-PL Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003999-79-NL Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003999-79-IT Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003999-79-FI Argentina;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003999-79-ES Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003999-79-CZ Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2015-004000-35-FR Argentina;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2015-004000-35-CZ Argentina;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2015-003999-79-GB Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2015-003999-79-FR Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2015-003999-79-EE Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2015-003999-79-Outside-EU/EEA Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
SB4 (etanercept biosimilar)
Samsung Bioepis Co., Ltd.
2013 Phase 3 EUCTR2012-005026-30-HU Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-PL Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-CZ Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-BG Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
SB5
Samsung Bioepis Co., Ltd
2015 - EUCTR2014-004887-39-PL Poland;
Samsung Bioepis Co., Ltd.
2014 Phase 3 EUCTR2013-005013-13-BG Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-PL Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-LT Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
SSGJ-613
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2021 Phase 1 NCT05027373 China;
SUB180983
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 3 EUCTR2019-000119-10-IT European Union;France;Germany;Italy;United Kingdom;
Sarilumab
Sanofi
2016 Phase 2 NCT02776735 Argentina;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Sarilumab SAR153191 (REGN88)
Sanofi
2018 Phase 2 NCT02991469 Argentina;Bulgaria;Canada;Chile;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Sedatives/Hypnotics,Other
University of Oulu
2017 Phase 4 NCT03069638 Finland;
Somatropin
Royal Hospital For Sick Children, Yorkhill Division
2004 - EUCTR2004-004153-25-GB United Kingdom;
Sulfasalazine
Pfizer
2010 Phase 4 NCT00637780 Canada;Mexico;United States;
TC-MSC
University Medical Center Utrecht
2014 - EUCTR2012-002067-10-NL Netherlands;
TNFR:Fc
Samsung Bioepis Co., Ltd.
2013 Phase 3 EUCTR2012-005026-30-HU Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-PL Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-CZ Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-BG Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
TRIAMCINOLONE HEXACETONIDE
Oslo University Hospital
2020 Phase 4 EUCTR2019-000889-38-NO Norway;
Taltz (80 mg solution for injection in pre-filled syringe)
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Eli Lilly and Company
2021 Phase 3 EUCTR2018-000681-10-CZ Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-GB Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DK Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DE Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-NL Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-FR Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-BE Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Tocilizumab
Clinical Immunology, Jichi Medical University
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 3 EUCTR2016-000312-15-FR France;
Assistance Publique - Hôpitaux de Paris
2017 Phase 3 NCT02840175 France;
Children's Hospital of Chongqing Medical University
2017 - ChiCTR-OPB-17013704 China;
2016 - ChiCTR-OPC-17011391 China;
Division of Rheumatology &
Eric B. Suhler
2013 Phase 1/Phase 2 NCT01603355 United States;
F. Hoffmann-La Roche Limited
2008 - EUCTR2007-000872-18-SK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-DK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
F. Hoffmann-La Roche Ltd
2015 Phase 1 EUCTR2015-000435-33-PL Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-HU Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-GB Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-DE Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-BE Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2010 - EUCTR2009-011593-15-NL Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011593-15-GB Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 Phase 3 EUCTR2009-011593-15-BE Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 - EUCTR2009-011593-15-FR Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-011593-15-DE Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 1 EUCTR2015-000435-33-FR Argentina;Belgium;Canada;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd.
2012 Phase 4 EUCTR2012-000444-10-SE Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-GB Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-ES Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-DE Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2007-000872-18-GB Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-DE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-CZ Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-BE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 4 EUCTR2012-000444-10-NO Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
Hoffmann-La Roche
2018 Phase 4 NCT03301883 China;
2014 Phase 1 NCT02165345 Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 4 NCT01734382 Argentina;Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;United States;
2013 Phase 1 NCT01904292 Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 NCT01904279 Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2012 Phase 1 NCT01455701 Argentina;Belgium;Canada;France;Germany;Hungary;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 Phase 3 NCT00988221 Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
ROCHE
2008 - EUCTR2007-000872-18-IT Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
Roche Farma S.A en nombre de F. Hoffmann-La Roche Ltd
2015 Phase 1 EUCTR2015-000435-33-ES Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
Shenzhen Children's Hospital
2017 - ChiCTR-INR-17011829 China;
Tufts Medical Center
2009 - NCT00868751 United States;
University Hospitals Bristol NHS Foundation Trust
2015 Phase 2 EUCTR2015-001323-23-GB United Kingdom;
University of Oklahoma
2009 - NCT00862758 United States;
Yokohama City University Hospital Department of Pediatrics
2016 - JPRN-UMIN000024178 Japan;
Tocilizumab Roche
F. Hoffmann-La Roche Limited
2008 - EUCTR2007-000872-18-SE Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-NL Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-ES Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2007-000872-18-NO Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
F. Hoffmann-La Roche Ltd.
2008 Phase 3 EUCTR2007-000872-18-GR Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
Tocilizumab SC
F. Hoffmann-La Roche Ltd
2014 Phase 1 EUCTR2013-005212-98-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 1 EUCTR2013-005212-98-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2012-003490-26-Outside-EU/EEA Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd.
2013 Phase 1 EUCTR2012-003486-18-PL Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2012-003486-18-Outside-EU/EEA Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
Tocilizumab [RoActemra/Actemra]
Hoffmann-La Roche
2013 Phase 3 NCT01727986 Brazil;
2012 Phase 3 NCT01673919 France;
2012 Phase 3 NCT01667471 Germany;
2008 Phase 3 NCT00642460 Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
Tofacitinib
PFIZER INC.
2013 - EUCTR2011-004915-22-IT Argentina;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;
2012 - EUCTR2011-004914-40-IT Argentina;Hungary;Italy;Mexico;Poland;Russian Federation;
Pfizer
2013 Phase 3 NCT01500551 Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Hungary;Israel;Mexico;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc
2012 Phase 2;Phase 3 EUCTR2011-004915-22-SK Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2012 Phase 1 EUCTR2011-004914-40-HU Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
2012 - EUCTR2011-004914-40-SK Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
2012 - EUCTR2011-004914-40-PL Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
2018 Phase 2;Phase 3 EUCTR2011-004915-22-BE Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-004915-22-PL Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-004915-22-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-004915-22-HU Czech Republic;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Slovakia;
- Phase 2;Phase 3 EUCTR2011-004915-22-NL Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc.
2018 Phase 2;Phase 3 EUCTR2011-004915-22-GB Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Tofacitinib citrate
PFIZER INC
2020 Phase 3 EUCTR2017-002018-29-IT Argentina;Belgium;Brazil;Canada;Chile;China;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
- Phase 2;Phase 3 EUCTR2011-004915-22-SE Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Tofacitinibe citrate
Pfizer Inc
2012 Phase 2;Phase 3 EUCTR2011-004915-22-SK Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
2018 Phase 2;Phase 3 EUCTR2011-004915-22-BE Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc.
2020 Phase 3 EUCTR2017-002018-29-SK Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc. 235 East 42nd Street, New York, New York 10017
2022 Phase 3 EUCTR2017-002018-29-HU Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-NL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-DE Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2017-002018-29-PL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-SE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-BE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Triamcinolone Hexacetonide 20 MG/ML
Oslo University Hospital
2020 Phase 4 NCT04614311 Norway;
Upadacitinib
ABBVIE DEUTSCHLAND GMBH & CO. KG
2019 Phase 1 EUCTR2018-000715-25-IT Germany;Hungary;Italy;Spain;United States;
AbbVie
2019 Phase 1 NCT03725007 Germany;Hungary;Israel;Italy;Puerto Rico;Spain;United States;
AbbVie Deutschland GmbH & Co. KG
2019 Phase 1;Phase 3 EUCTR2018-000715-25-ES Germany;Hungary;Italy;Spain;United States;
2019 Phase 1 EUCTR2018-000715-25-HU Germany;Hungary;Italy;Spain;United States;
2019 Phase 1 EUCTR2018-000715-25-DE Germany;Hungary;Italy;Spain;United States;
VIMOVO 250/20
Horizon Pharma Ireland, Ltd., Dublin Ireland
2012 Phase 4 NCT01544114 United States;
VIMOVO 375/20
Horizon Pharma Ireland, Ltd., Dublin Ireland
2012 Phase 4 NCT01544114 United States;
VIMOVO 500/20
Horizon Pharma Ireland, Ltd., Dublin Ireland
2012 Phase 4 NCT01544114 United States;
VSL#3
Assistance Publique - Hôpitaux de Paris
2017 - NCT03092427 France;
Vitamin B3
UMC Utrecht
2019 Phase 1;Phase 2 EUCTR2018-002245-11-NL Netherlands;
Yellow Fever vaccine (17D)
University of Sao Paulo General Hospital
2018 - NCT03430388 Brazil;
ibuprofen/26.6 mg famotidine
Horizon Pharma Ireland, Ltd., Dublin Ireland
2012 Phase 4 NCT01563185 United States;
Centre Hospitalier Universitaire, Amiens
2019 - NCT03984669 France;
(1-3)-ß-D-Glucan (BDG) assay (Fungitell)
Centre Hospitalier Universitaire, Amiens
2019 - NCT03984669 France;
- SOLUZIONE INIETTABILE IN SIRINGHE PRE-RIEMPITE- USO SOTTOCUTANEO- SIRINGA PRERIEMPITA (0,4ML)- 2 SIRINGHE PRE-RIEMPITE + 2 TAMPONI IMBEVUTI DI ALCOOL
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
0.4mL prefilled syringes
Bristol-Myers Squibb International Corporation
2013 Phase 3 EUCTR2012-003195-39-IT Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-ES Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-DE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-BE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- Phase 3 EUCTR2012-003195-39-FR Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- - EUCTR2012-003195-39-Outside-EU/EEA Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
0.7mL prefilled syringes
Bristol-Myers Squibb International Corporation
2013 Phase 3 EUCTR2012-003195-39-IT Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-ES Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-DE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-BE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- Phase 3 EUCTR2012-003195-39-FR Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- - EUCTR2012-003195-39-Outside-EU/EEA Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
1mL prefilled syringes
Bristol-Myers Squibb International Corporation
2013 Phase 3 EUCTR2012-003195-39-IT Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-ES Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-DE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-BE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- Phase 3 EUCTR2012-003195-39-FR Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- - EUCTR2012-003195-39-Outside-EU/EEA Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
98-92-0
UMC Utrecht
2019 Phase 1;Phase 2 EUCTR2018-002245-11-NL Netherlands;
- Phase 1;Phase 2 EUCTR2016-003643-10-NL Netherlands;
ABT-494
ABBVIE DEUTSCHLAND GMBH & CO. KG
2019 Phase 1 EUCTR2018-000715-25-IT Germany;Hungary;Italy;Spain;United States;
AbbVie Deutschland GmbH & Co. KG
2019 Phase 1;Phase 3 EUCTR2018-000715-25-ES Germany;Hungary;Italy;Spain;United States;
2019 Phase 1 EUCTR2018-000715-25-HU Germany;Hungary;Italy;Spain;United States;
2019 Phase 1 EUCTR2018-000715-25-DE Germany;Hungary;Italy;Spain;United States;
ACZ885
NOVARTIS FARMA
2009 - EUCTR2008-008008-42-IT Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-IT Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
NOVARTIS FARMA S.p.A.
2014 Phase 3;Phase 4 EUCTR2013-004867-29-IT Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
NOVARTIS PHARMA AG
2006 - EUCTR2006-001834-42-IT France;Italy;United Kingdom;
Novartis
2006 Phase 1/Phase 2 NCT00426218 Italy;
Novartis Farmaceutica, S.A.
2013 - EUCTR2012-003054-92-ES Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Novartis Farmacéutica S.A.
2009 Phase 3 EUCTR2008-005476-27-ES Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-ES Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-ES Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
Novartis Farmacéutica, S.A.
2014 Phase 3;Phase 4 EUCTR2013-004867-29-ES Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
Novartis Pharma K.K.
2015 Phase 3 JPRN-JapicCTI-152865 -
Novartis Pharma S.A.S
2014 Phase 4 EUCTR2014-002872-95-FR France;
Novartis Pharma Services AG
2014 Phase 3;Phase 4 EUCTR2013-004867-29-SE Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
2014 Phase 3;Phase 4 EUCTR2013-004867-29-NL Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
2014 Phase 3;Phase 4 EUCTR2013-004867-29-HU Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
2014 Phase 3;Phase 4 EUCTR2013-004867-29-DE Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
2014 Phase 3;Phase 4 EUCTR2013-004867-29-BE Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
2014 Phase 3;Phase 4 EUCTR2013-004867-29-AT Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
2013 - EUCTR2012-003054-92-CZ Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2012-003054-92-AT Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2010 - EUCTR2008-008008-42-GR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-008008-42-AT Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2010 - EUCTR2008-005479-82-GR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005476-27-GR Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005476-27-GB Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005479-82-FR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005479-82-BE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005476-27-FR Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-SE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Russian Federation;Spain;Swaziland;Sweden;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-NL Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-HU Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-GB Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-FR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-DK Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-DE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-BE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-005479-82-SE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-HU Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-GB Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-DK Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-DE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-AT Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-SE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-HU Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-DK Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-DE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-BE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2012-003054-92-BE Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2008-008008-42-NO Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-005479-82-NO Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-005476-27-NO Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
- - EUCTR2008-005479-82-Outside-EU/EEA Argentina;Brazil;Canada;Israel;Peru;Switzerland;Turkey;United States;
- - EUCTR2008-005476-27-Outside-EU/EEA Argentina;Brazil;Israel;Peru;Switzerland;Turkey;United States;
Novartis PharmaServices AG
- - EUCTR2008-008008-42-Outside-EU/EEA Argentina;Brazil;Canada;Israel;Peru;Russian Federation;South Africa;Switzerland;Turkey;United States;
Novartis Pharmaceuticals
2013 Phase 3 NCT01676948 Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
ACZ885 150 mg (Canakinumab)
Novartis Pharmaceuticals
2014 Phase 3 NCT02296424 Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
ACZ885 Drug Substance
Novartis Pharma Services AG
2007 Phase 2 EUCTR2006-001834-42-GB France;Italy;United Kingdom;
2007 - EUCTR2006-001834-42-FR France;Italy;United Kingdom;
ACZ885G
NOVARTIS FARMA
2009 - EUCTR2008-005476-27-IT Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
AIN457
NOVARTIS PHARMA AG
2019 Phase 3 EUCTR2018-002521-30-IT Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
- Phase 3 EUCTR2016-003761-26-IT Belgium;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
Novartis Farmacéutica S.A.
2017 Phase 3 EUCTR2016-003761-26-ES Belgium;Germany;Italy;Netherlands;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
Novartis Farmacéutica, S.A.
2019 Phase 3 EUCTR2018-002521-30-ES Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
Novartis Pharma AG
2019 Phase 3 EUCTR2018-002521-30-DE Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
2017 Phase 3 EUCTR2016-003761-26-PL Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003761-26-GB Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003761-26-DE Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003761-26-BE Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2018-002521-30-PL Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
- Phase 3 EUCTR2018-002521-30-BE Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
Novartis Pharmaceuticals
2019 Phase 3 NCT03769168 Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
2017 Phase 3 NCT03031782 Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
AIN457F
NOVARTIS PHARMA AG
- Phase 3 EUCTR2016-003761-26-IT Belgium;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
AMG-407
Amgen Inc.
2021 Phase 3 EUCTR2019-002788-88-NL Austria;Belgium;France;Italy;Netherlands;
2021 Phase 3 EUCTR2019-002788-88-FR Austria;Belgium;France;Netherlands;
- Phase 3 EUCTR2019-002788-88-PL Austria;Belgium;France;Italy;Netherlands;Poland;
- Phase 3 EUCTR2019-002788-88-BE Austria;Belgium;Netherlands;
- Phase 3 EUCTR2019-002788-88-AT Austria;Belgium;France;Italy;Netherlands;
AMG407
AMGEN INC.
2021 Phase 3 EUCTR2019-002788-88-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;
Amgen Inc.
2021 Phase 3 EUCTR2019-002788-88-NL Austria;Belgium;France;Italy;Netherlands;
2021 Phase 3 EUCTR2019-002788-88-FR Austria;Belgium;France;Netherlands;
- Phase 3 EUCTR2019-002788-88-PL Austria;Belgium;France;Italy;Netherlands;Poland;
- Phase 3 EUCTR2019-002788-88-BE Austria;Belgium;Netherlands;
- Phase 3 EUCTR2019-002788-88-AT Austria;Belgium;France;Italy;Netherlands;
APD421
Pfizer Inc
2012 Phase 2;Phase 3 EUCTR2011-004915-22-SK Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
2018 Phase 2;Phase 3 EUCTR2011-004915-22-BE Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2011-004915-22-SE Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc.
2020 Phase 3 EUCTR2017-002018-29-SK Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc. 235 East 42nd Street, New York, New York 10017
2022 Phase 3 EUCTR2017-002018-29-HU Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-NL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-DE Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2017-002018-29-PL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-SE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-BE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Abalimumab bio-originatore
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
Abatacept
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 3 EUCTR2016-000312-15-FR France;
Assistance Publique - Hôpitaux de Paris
2017 Phase 3 NCT02840175 France;
Bristol-Myers Squibb
2013 Phase 3 NCT01844518 Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 NCT01835470 Japan;
Bristol-Myers Squibb K.K.
2013 Phase 3 JPRN-JapicCTI-132119 Japan;
Yokohama City University Hospital Department of Pediatrics
2016 - JPRN-UMIN000024178 Japan;
Abatacept Injection
Duke University
2019 Phase 3 NCT03841357 United States;
Actemra
F. Hoffmann-La Roche Limited
2008 - EUCTR2007-000872-18-SK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-ES Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-DK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
Actemra, MRA
F. Hoffmann-La Roche Limited
- Phase 3 EUCTR2007-000872-18-NO Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
Adalimumab
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 3 EUCTR2016-000312-15-FR France;
AbbVie
2008 - NCT00783510 Australia;Austria;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Portugal;Puerto Rico;Slovakia;Spain;Sweden;United States;
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00775437 Czech Republic;Denmark;France;Germany;Puerto Rico;Slovakia;Sweden;United States;
Assistance Publique - Hôpitaux de Paris
2017 Phase 3 NCT02840175 France;
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Eli Lilly and Company
2021 Phase 3 NCT04527380 Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom;
2019 Phase 3 NCT04088409 France;Germany;Italy;Spain;United Kingdom;
F.I. Proctor Foundation, University of California San Francisco
2019 Phase 4 EUCTR2019-000412-29-GB Australia;United Kingdom;United States;
Nisha Acharya
2020 Phase 4 NCT03816397 Australia;United Kingdom;United States;
Adalimumab (20mg)
University Hospitals Bristol NHS Foundation Trust
2011 Phase 2 EUCTR2010-021141-41-GB United Kingdom;
Adalimumab (40mg)
University Hospitals Bristol NHS Foundation Trust
2011 Phase 2 EUCTR2010-021141-41-GB United Kingdom;
Adalimumab biosimilare
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
Alfacalcidol 2 micrograms/ml
Belfast Health and Social Care Trust, Musgrave Park Hospital
2006 Phase 4 EUCTR2005-003129-23-GB United Kingdom;
Ambirix
Public Health Service Amsterdam
2009 - EUCTR2008-003280-40-NL Netherlands;
Anakinra
ISTITUTO GIANNINA GASLINI
2005 - EUCTR2005-004008-36-IT Italy;
Institut National de la Santé Et de la Recherche Médicale, France
2006 Phase 2/Phase 3 NCT00339157 France;
Swedish Orphan Biovitrum
2019 - NCT03932344 Italy;
Anakinra / kineret
University Medical Center Utrecht
2016 Phase 4 EUCTR2015-004393-16-NL Netherlands;
Anti-TNF
University of Sao Paulo
2008 Phase 4 NCT02196480 Brazil;
Anti-pandemic H1N1 influenza vaccine
University of Sao Paulo
2010 Phase 4 NCT01151644 Brazil;
Anti-tumor necrosis factor alpha monoclonal antibody
Assistance Publique - Hôpitaux de Paris
2011 Phase 2/Phase 3 NCT01385826 France;
Antivirale ad uso diretto
Swedish Orphan Biovitrum AG
- Phase 2;Phase 3 EUCTR2021-001577-24-IT Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Apremilast
AMGEN INC.
2021 Phase 3 EUCTR2019-002788-88-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;
Amgen Inc.
2021 Phase 3 EUCTR2019-002788-88-NL Austria;Belgium;France;Italy;Netherlands;
2021 Phase 3 EUCTR2019-002788-88-FR Austria;Belgium;France;Netherlands;
- Phase 3 EUCTR2019-002788-88-PL Austria;Belgium;France;Italy;Netherlands;Poland;
- Phase 3 EUCTR2019-002788-88-BE Austria;Belgium;Netherlands;
- Phase 3 EUCTR2019-002788-88-AT Austria;Belgium;France;Italy;Netherlands;
BMS-188667
Bristol-Myers Squibb International Corporation
2013 Phase 3 EUCTR2012-003195-39-IT Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-ES Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-DE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
2013 Phase 3 EUCTR2012-003195-39-BE Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- Phase 3 EUCTR2012-003195-39-FR Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
- - EUCTR2016-000940-32-Outside-EU/EEA Japan;
- - EUCTR2012-003195-39-Outside-EU/EEA Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
Baricitinib
Eli Lilly and Company
2020 Phase 3 NCT04088396 Argentina;Austria;Belgium;Brazil;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 NCT04088409 France;Germany;Italy;Spain;United Kingdom;
2019 Phase 3 NCT03773965 Argentina;Australia;Austria;Belgium;Brazil;China;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2018 Phase 3 NCT03773978 Argentina;Australia;Austria;Belgium;Brazil;China;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Biological DMARDs
Hoffmann-La Roche
2000 - NCT02784808 -
Biosimilar Etanercept
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
Biosimilar adalimumab
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
Blood sample
University Hospital, Montpellier
2014 - NCT02067962 -
Bof-, Mazelen-, Rubellavaccin, poeder voor injectievloeistof
University Medical Center Utrecht
2008 - EUCTR2007-001861-14-NL Netherlands;
CCP-690-550-10
PFIZER INC
2020 Phase 3 EUCTR2017-002018-29-IT Argentina;Belgium;Brazil;Canada;Chile;China;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
CNTO 148 (Golimumab)
Janssen Research & Development, LLC
2010 Phase 3 NCT01230827 Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;United States;
CNTO148
Janssen Biologics B.V.
2011 Phase 3 EUCTR2009-015019-42-BE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2011 - EUCTR2009-015019-42-DE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
2010 - EUCTR2009-015019-42-LT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-FI Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-AT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
- - EUCTR2009-015019-42-Outside-EU/EEA Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA
NOVARTIS PHARMA AG
- Phase 3 EUCTR2016-003761-26-IT Belgium;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE
NOVARTIS PHARMA AG
2019 Phase 3 EUCTR2018-002521-30-IT Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
CP-690, 550-10
PFIZER INC
2020 Phase 3 EUCTR2017-002018-29-IT Argentina;Belgium;Brazil;Canada;Chile;China;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
CP-690,550
PFIZER INC.
2013 - EUCTR2011-004915-22-IT Argentina;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;
Pfizer
2013 Phase 1 NCT01513902 Germany;Hungary;Poland;Slovakia;United States;
CP-690,550 (tofacitinib)
Pfizer
2016 Phase 3 NCT02592434 Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
CP-690,550-10
PFIZER INC.
2012 - EUCTR2011-004914-40-IT Argentina;Hungary;Italy;Mexico;Poland;Russian Federation;
Pfizer Inc
2012 Phase 2;Phase 3 EUCTR2011-004915-22-SK Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2012 Phase 1 EUCTR2011-004914-40-HU Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
2012 - EUCTR2011-004914-40-SK Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
2012 - EUCTR2011-004914-40-PL Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
2019 Phase 3 EUCTR2015-001438-46-PL Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2015-001438-46-ES Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2015-001438-46-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2015-001438-46-BE Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2011-004915-22-BE Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-004915-22-PL Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-004915-22-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-004915-22-HU Czech Republic;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Slovakia;
- Phase 2;Phase 3 EUCTR2011-004915-22-SE Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2011-004915-22-NL Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc.
2020 Phase 3 EUCTR2017-002018-29-SK Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2015-001438-46-GB Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2011-004915-22-GB Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc. 235 East 42nd Street, New York, New York 10017
2022 Phase 3 EUCTR2017-002018-29-HU Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-NL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-DE Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2017-002018-29-PL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-SE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-BE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
CP-690-550-10 (DMID D1600180)
Pfizer Inc
2012 Phase 2;Phase 3 EUCTR2011-004915-22-SK Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
2018 Phase 2;Phase 3 EUCTR2011-004915-22-BE Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2011-004915-22-SE Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc.
2020 Phase 3 EUCTR2017-002018-29-SK Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc. 235 East 42nd Street, New York, New York 10017
2022 Phase 3 EUCTR2017-002018-29-HU Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-NL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-DE Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2017-002018-29-PL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-SE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-BE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
CSs
Hoffmann-La Roche
2018 Phase 4 NCT03301883 China;
Canakinumab
NOVARTIS FARMA
2009 - EUCTR2008-008008-42-IT Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-IT Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-IT Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
Novartis Farmacéutica S.A.
2009 Phase 3 EUCTR2008-005476-27-ES Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-ES Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-ES Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
Novartis Pharma K.K.
2015 Phase 3 JPRN-JapicCTI-152865 -
Novartis Pharma Services AG
2010 - EUCTR2008-008008-42-GR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005479-82-GR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005476-27-GR Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005476-27-GB Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005479-82-FR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005479-82-BE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005476-27-FR Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-SE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Russian Federation;Spain;Swaziland;Sweden;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-GB Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-FR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-DK Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-DE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-005479-82-SE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-HU Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-GB Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-DK Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-DE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-AT Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-SE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-HU Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-DK Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-DE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-BE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-008008-42-NO Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-005479-82-NO Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-005476-27-NO Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
Novartis Pharmaceuticals
2015 Phase 3 NCT02396212 Japan;
2014 Phase 3 NCT02334748 France;
2013 Phase 3 NCT01676948 Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 Phase 3 NCT00891046 Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 Phase 3 NCT00889863 Argentina;Belgium;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;South Africa;Spain;Sweden;Switzerland;Turkey;United States;
2009 Phase 3 NCT00886769 Argentina;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Celebrex
Pfizer Inc
- - EUCTR2014-003737-26-Outside-EU/EEA Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Ukraine;United States;
Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009 Phase 4 NCT00807846 Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Switzerland;Ukraine;United States;
2009 - NCT00688545 United States;
Certolizumab Pegol (CZP)
UCB BIOSCIENCES GmbH
2012 Phase 3 NCT01550003 Argentina;Brazil;Canada;Chile;Mexico;Russian Federation;United States;
Cervarix suspensie voor injectie
University Medical Center Utrecht
2009 - EUCTR2008-008169-36-NL Netherlands;
Collection of samples
Institut National de la Santé Et de la Recherche Médicale, France
2021 - NCT04902807 -
Combination of DMARDs
Helsinki University Central Hospital
2003 Phase 3 NCT01015547 Finland;
Corticosteroids
Hoffmann-La Roche
2008 Phase 3 NCT00642460 Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
Cyclosporine A
St. Franziskus Hospital
1991 - NCT00404482 Germany;
Daclizumab
National Eye Institute (NEI)
2005 Phase 2 NCT00130637 United States;
Dexmedetomidine
University of Oulu
2017 Phase 4 NCT03069638 Finland;
Diethyl-[6-(4-hydroxycarbamoyl- phenyl carbamoyloxymethyl)-naphthalen-2-yl methyl]-ammonium chloride
Italfarmaco S.p.A.
2011 - EUCTR2011-003341-18-CZ Czech Republic;
Double-Blind Adalimumab
Abbott
2002 Phase 3 NCT00048542 Belgium;Czech Republic;France;Germany;Italy;Slovakia;Spain;United States;
ENBREL 25 mg/ml polvo y disolvente para solución inyectable para uso pediátrico
PFIZER, S.L.U.
2011 - EUCTR2010-023802-10-ES Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States
2012 Phase 3 EUCTR2010-023802-10-NL Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
ENBREL 50 mg solución inyectable en jeringas precargadas
PFIZER, S.L.U.
2011 - EUCTR2010-023802-10-ES Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States
2012 Phase 3 EUCTR2010-023802-10-NL Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
ENBREL*BB SC 4FL 25MG 1ML+4SIR
Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
2010 - EUCTR2009-012520-84-IT Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
EU/1/03/256/001
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
EU/1/07/389/001
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
EU/1/99/126/001
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
EX VIVO CULTURED HUMAN MESENCHYMAL STEM CELLS
University Medical Center Utrecht
2014 - EUCTR2012-002067-10-NL Netherlands;
Emapalumab
Novimmune SA
2017 Phase 2 EUCTR2016-004223-23-ES France;Germany;Italy;Netherlands;Spain;United Kingdom;
Swedish Orphan Biovitrum
2018 Phase 2 NCT03311854 France;Italy;Netherlands;Spain;United Kingdom;United States;
Swedish Orphan Biovitrum AG
- Phase 2;Phase 3 EUCTR2021-001577-24-IT Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Swedish Orphan Biovitrum AG (Sobi AG)
2021 Phase 2;Phase 3 EUCTR2021-001577-24-PL Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2021-001577-24-ES Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2021-001577-24-SE Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2021-001577-24-FR Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2021-001577-24-CZ Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Enbrel
IRCCS Istituto Giannina Gaslini
2019 Phase 3 EUCTR2018-001931-27-IT Italy;
PFIZER INC.
2012 - EUCTR2010-023802-10-IT Australia;Belgium;Colombia;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Russian Federation;Slovakia;Slovenia;Spain;
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
Wyeth Kabushiki Kaisha (Wyeth K.K.)
- - EUCTR2014-004103-73-Outside-EU/EEA Japan;
Wyeth Pharmaceuticals Inc, (a Pfizer Company) 500 Arcola Road, Collegeville, PA 19426 USA
2010 - EUCTR2009-012520-84-CZ Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 Phase 3 EUCTR2009-012520-84-BE Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovakia;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-SI Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-LV Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-LT Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-DE Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
- - EUCTR2009-012520-84-Outside-EU/EEA Australia;Colombia;Mexico;Russian Federation;Serbia;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
2009 Phase 3 EUCTR2009-012520-84-SK Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company, Philadelphia, PA-19101, USA
2010 - EUCTR2009-012520-84-DK Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-SE Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
2010 Phase 3 EUCTR2009-012520-84-GR Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
2010 - EUCTR2009-012520-84-NL Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
2009 Phase 3 EUCTR2009-012520-84-ES Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-HU Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-FR Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
Enbrel (Etanercept)
Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320
- - EUCTR2012-001171-37-Outside-EU/EEA Canada;United States;
- - EUCTR2012-001145-40-Outside-EU/EEA Canada;United States;
Enbrel®
Asklepios-Klinik Sankt Augustin
2007 - EUCTR2007-000255-34-DE Germany;
Pfizer Inc.235 East 42nd Street, New York, NY 10017
2012 Phase 3 EUCTR2010-023802-10-NO Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-SK Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-SI Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-LV Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-LT Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-HU Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-FR Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-DE Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-CZ Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2011 Phase 3 EUCTR2010-023802-10-BE Australia;Belgium;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
- Phase 3 EUCTR2010-023802-10-PL Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
- - EUCTR2010-023802-10-Outside-EU/EEA Australia;Colombia;Mexico;Russian Federation;Serbia;
Samsung Bioepis Co., Ltd.
2013 Phase 3 EUCTR2012-005026-30-HU Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-PL Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-CZ Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-BG Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
Entecavir
Seoul National University Hospital
2012 Phase 3 NCT01694264 Korea, Republic of;
Esomeprazole
AstraZeneca
2011 Phase 1 NCT01358383 United States;
Etanercept
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 3 EUCTR2016-000312-15-FR France;
Assistance Publique - Hôpitaux de Paris
2017 Phase 3 NCT02840175 France;
Erasmus Medical Center
2011 Phase 4 NCT01287715 Netherlands;
Pfizer
2011 Phase 3 NCT01421069 Australia;Belgium;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
2009 Phase 3 NCT00962741 Argentina;Australia;Belgium;Brazil;Colombia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;Sweden;Taiwan;
Wyeth Pharmaceuticals Inc, (a Pfizer Company) 500 Arcola Road, Collegeville, PA 19426 USA
2010 - EUCTR2009-012520-84-CZ Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 Phase 3 EUCTR2009-012520-84-BE Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovakia;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-SI Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-LV Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-LT Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-DE Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
- - EUCTR2009-012520-84-Outside-EU/EEA Australia;Colombia;Mexico;Russian Federation;Serbia;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
2009 Phase 3 EUCTR2009-012520-84-SK Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company, Philadelphia, PA-19101, USA
2010 - EUCTR2009-012520-84-DK Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-SE Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
2010 Phase 3 EUCTR2009-012520-84-GR Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
2010 - EUCTR2009-012520-84-NL Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
2010 - EUCTR2009-012520-84-IT Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
2009 Phase 3 EUCTR2009-012520-84-ES Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-HU Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
2009 - EUCTR2009-012520-84-FR Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
Wyeth is now a wholly owned subsidiary of Pfizer
2003 - NCT00195377 Spain;
Etanercept (genetical recombination)
Pfizer
2009 - NCT01145352 Japan;
Etanercept Optimal dosing
Duke University
2023 Phase 1 NCT04585711 United States;
Etanercept biosimilare
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
Folic/folinic acid
University of British Columbia
2019 - NCT04169828 Canada;
Fully human anti-interferon gamma monoclonal antibody
Novimmune SA
- Phase 2 EUCTR2016-004223-23-FR Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
Genakumab
GeneScience Pharmaceuticals Co., Ltd.
2019 Phase 1 NCT04337437 China;
Genicular nerve block
Sohag University
2020 Phase 4 NCT04687930 Egypt;
Genotropin
Ludwig-Maximilians - University of Munich
1996 Phase 3 NCT00420251 Germany;
Pfizer Inc
- - EUCTR2014-004105-32-Outside-EU/EEA France;
Pharmacia & Upjohn S.A.
- - EUCTR2014-004104-30-Outside-EU/EEA France;
Givinostat
ITALFARMACO
2010 - EUCTR2010-019094-15-IT Czech Republic;Italy;Slovenia;Spain;
Italfarmaco
2011 - NCT01557452 Czech Republic;
2010 Phase 2 NCT01261624 Belgium;Czech Republic;Italy;Romania;Serbia;Slovenia;Spain;
Givinostat (hydrochloride-monohydrate)
Italfarmaco S.p.A.
2011 - EUCTR2011-003341-18-CZ Czech Republic;
2010 Phase 2 EUCTR2010-019094-15-BE Belgium;Czech Republic;Italy;Slovenia;Spain;
2010 - EUCTR2010-019094-15-SI Czech Republic;Italy;Slovenia;Spain;
2010 - EUCTR2010-019094-15-ES Czech Republic;Italy;Slovenia;Spain;
2010 - EUCTR2010-019094-15-CZ Czech Republic;Italy;Slovenia;Spain;
Golimumab
Janssen Research & Development, LLC
2014 Phase 3 NCT02277444 Argentina;Brazil;Canada;Chile;Israel;Mexico;Puerto Rico;Russian Federation;South Africa;United States;
Medical University of Graz
2010 - NCT04200833 -
Golimumab Liquid in prefilled syringe
Janssen Biologics B.V.
2011 Phase 3 EUCTR2009-015019-42-BE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2011 - EUCTR2009-015019-42-DE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
2010 - EUCTR2009-015019-42-LT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-FI Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-AT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
- - EUCTR2009-015019-42-Outside-EU/EEA Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
HUMIRA
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 3 EUCTR2016-000312-15-FR France;
Heparin
Shanghai Children's Medical Center
2015 - ChiCTR-OOC-15006228 China;
Human anti-TNF-alpha monoclonal antibody
Janssen Biologics B.V.
2011 Phase 3 EUCTR2009-015019-42-BE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2011 - EUCTR2009-015019-42-DE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
2010 - EUCTR2009-015019-42-LT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-FI Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-AT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
- - EUCTR2009-015019-42-Outside-EU/EEA Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
Humira
AbbVie Deutschland GmbH & Co. KG
2010 - EUCTR2009-013091-40-SE Czech Republic;France;Germany;Sweden;
2010 - EUCTR2009-013091-40-CZ Czech Republic;France;Germany;Sweden;
Abbott GmbH & Co. KG
2010 Phase 3 EUCTR2009-013091-40-SK Czech Republic;Denmark;France;Germany;Slovakia;Sweden;
2010 Phase 3 EUCTR2009-013091-40-FR Czech Republic;Denmark;France;Germany;Slovakia;Sweden;
2010 Phase 3 EUCTR2009-013091-40-DK Czech Republic;Denmark;France;Germany;Sweden;
2010 - EUCTR2009-013091-40-DE Czech Republic;France;Germany;Sweden;
- - EUCTR2009-013091-40-Outside-EU/EEA -
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-IT European Union;France;Germany;Italy;United Kingdom;
Eli Lilly and Company
2021 Phase 3 EUCTR2018-000681-10-CZ Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2019-000119-10-DE France;Germany;Italy;Spain;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-GB Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DK Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DE Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-GB France;Germany;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-FR France;Germany;United Kingdom;
- Phase 3 EUCTR2018-000681-10-NL Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-FR Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-BE Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
F.I. Proctor Foundation, University of California San Francisco
2019 Phase 4 EUCTR2019-000412-29-GB Australia;United Kingdom;United States;
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
Humira®
Samsung Bioepis Co., Ltd.
2014 Phase 3 EUCTR2013-005013-13-BG Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-PL Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-LT Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
IL-2
The First Hospital of Jilin University
2020 - NCT04397107 China;
IL-6 receptor inhibitor, recombinant humanized monoclonal antibody
F. Hoffmann-La Roche Ltd
2015 Phase 1 EUCTR2015-000435-33-PL Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-HU Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-GB Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-DE Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-BE Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011593-15-GB Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 Phase 3 EUCTR2009-011593-15-BE Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 1 EUCTR2015-000435-33-FR Argentina;Belgium;Canada;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd.
2012 Phase 4 EUCTR2012-000444-10-SE Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-GB Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-ES Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-DE Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2007-000872-18-GB Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-DE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-CZ Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-BE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 4 EUCTR2012-000444-10-NO Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
Roche Farma S.A en nombre de F. Hoffmann-La Roche Ltd
2015 Phase 1 EUCTR2015-000435-33-ES Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
ITF2357
ITALFARMACO
2006 - EUCTR2006-000089-35-IT Italy;
Italfarmaco
2006 Phase 2 NCT00570661 Former Serbia and Montenegro;Serbia;
Italfarmaco S.p.A.
2011 - EUCTR2011-003341-18-CZ Czech Republic;
2010 Phase 2 EUCTR2010-019094-15-BE Belgium;Czech Republic;Italy;Slovenia;Spain;
2010 - EUCTR2010-019094-15-SI Czech Republic;Italy;Slovenia;Spain;
2010 - EUCTR2010-019094-15-ES Czech Republic;Italy;Slovenia;Spain;
2010 - EUCTR2010-019094-15-CZ Czech Republic;Italy;Slovenia;Spain;
Ilaris
Asklepios Klink Sankt Augustin
2020 Phase 4 EUCTR2018-004284-30-DE Germany;
Novartis Farmacéutica, S.A.
2014 Phase 3;Phase 4 EUCTR2013-004867-29-ES Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
Novartis Pharma Services AG
2009 - EUCTR2008-008008-42-BE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
In double-blind phase: treatment with tofacitinib
Pfizer
2018 Phase 3 NCT03000439 Argentina;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
In open-label phase: treatment with tofacitinib
Pfizer
2018 Phase 3 NCT03000439 Argentina;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
Infliximab plus methotrexate
Helsinki University Central Hospital
2003 Phase 3 NCT01015547 Finland;
Influenza vaccine, Immune function
University of Pecs
2018 Early Phase 1 NCT03833271 Hungary;
Intra-articular steroid injection
Sohag University
2020 Phase 4 NCT04687930 Egypt;
Ixekizumab
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Eli Lilly and Company
2021 Phase 3 NCT04527380 Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom;
KINERET*SC 7SIR 100MG 0,67ML
ISTITUTO GIANNINA GASLINI
2005 - EUCTR2005-004008-36-IT Italy;
Kineret® or anakinra
University Medical Center Utrecht
2016 Phase 4 EUCTR2015-004393-16-NL Netherlands;
L01BA01
ISTITUTO GIANNINA GASLINI-PRINTO
2005 - EUCTR2005-001086-34-DK Denmark;Italy;Spain;
Istituto Giannina Gaslini-PRINTO
2005 - EUCTR2005-001086-34-ES Denmark;Italy;Spain;
L04AB04
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-IT European Union;France;Germany;Italy;United Kingdom;
Eli Lilly and Company
2020 Phase 3 EUCTR2019-000119-10-DE France;Germany;Italy;Spain;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-GB France;Germany;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-FR France;Germany;United Kingdom;
LY2439821
Eli Lilly and Company
2021 Phase 3 EUCTR2018-000681-10-CZ Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-GB Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DK Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DE Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-NL Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-FR Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-BE Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
LY3009104
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 3 EUCTR2019-000119-10-IT European Union;France;Germany;Italy;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-IT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004495-60-IT Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-IT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Eli Lilly and Company
2020 Phase 3 EUCTR2019-000119-10-DE France;Germany;Italy;Spain;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-GB France;Germany;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-FR France;Germany;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-PL Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-GB Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-FR Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-DK Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-DE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-CZ Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-BE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-AT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-PL Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-GB Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-FR Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-DK Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-DE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-CZ Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-BE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
- Phase 3 EUCTR2017-004471-31-AT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Lilly S.A.
2019 Phase 3 EUCTR2017-004518-24-ES Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-ES Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Lederspan
Oslo University Hospital
2020 Phase 4 EUCTR2019-000889-38-NO Norway;
Leflunomide
Mashhad University of Medical Sciences
2013 Phase 4 NCT02024334 Iran, Islamic Republic of;
Lidocaine
Sohag University
2021 Phase 3 NCT04775225 Egypt;
METHOTREXATE DISODIUM
University of Munster
2008 Phase 4 EUCTR2006-006812-31-DE Germany;Netherlands;
university medical centre utrecht
2007 Phase 4 EUCTR2006-006812-31-NL Germany;Netherlands;
METHOTREXATE*25CPR 2,
ISTITUTO GIANNINA GASLINI
2008 - EUCTR2008-006741-70-IT Italy;
MRA
F. Hoffmann-La Roche Limited
2008 - EUCTR2007-000872-18-SK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-DK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
MRA (Actemra)
F. Hoffmann-La Roche Ltd.
2008 Phase 3 EUCTR2007-000872-18-GR Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
MRA (tocilizumab)
Chugai Pharmaceutical Co., Ltd.
- Phase 3 JPRN-JapicCTI-050017 -
MRA(Tocilizumab)
Chugai Pharmaceutical
2005 Phase 3 NCT00144625 -
2004 Phase 3 NCT00144664 -
2004 Phase 3 NCT00144612 -
2004 Phase 3 NCT00144599 -
MRA, Actemra
F. Hoffmann-La Roche Limited
2008 - EUCTR2007-000872-18-SE Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-NL Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
MSB11022
Fresenius Kabi SwissBioSim GmbH
2019 Phase 1 NCT04018599 United States;
MTX
Hoffmann-La Roche
2018 Phase 4 NCT03301883 China;
Measles, Mumps, Rubella vaccination
N.M. Wulffraat
2008 Phase 4 NCT00731965 Netherlands;
Methotrexate
AbbVie
2008 - NCT00783510 Australia;Austria;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Portugal;Puerto Rico;Slovakia;Spain;Sweden;United States;
Hoffmann-La Roche
2008 Phase 3 NCT00642460 Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
ISTITUTO GIANNINA GASLINI
2005 - EUCTR2005-001086-34-IT Denmark;Italy;Spain;
ISTITUTO GIANNINA GASLINI-PRINTO
2005 - EUCTR2005-001086-34-DK Denmark;Italy;Spain;
Institute of Child Health
2006 - NCT00415935 United Kingdom;
Istituto Giannina Gaslini-PRINTO
2005 - EUCTR2005-001086-34-ES Denmark;Italy;Spain;
Janssen Research & Development, LLC
2014 Phase 3 NCT02277444 Argentina;Brazil;Canada;Chile;Israel;Mexico;Puerto Rico;Russian Federation;South Africa;United States;
2010 Phase 3 NCT01230827 Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;United States;
Leiden University
- Phase 4 EUCTR2018-001571-21-NL Netherlands;
University of British Columbia
2019 - NCT04169828 Canada;
Methotrexate - etanercept - prednisolone arm
Seattle Children's Hospital
2007 Phase 4 NCT00443430 United States;
Methotrexate alone
Helsinki University Central Hospital
2003 Phase 3 NCT01015547 Finland;
Methotrexate prefilled pen
medac GmbH
2014 Early Phase 1 NCT02052167 United States;
Metoject
University of Munster
2008 Phase 4 EUCTR2006-006812-31-DE Germany;Netherlands;
university medical centre utrecht
2007 Phase 4 EUCTR2006-006812-31-NL Germany;Netherlands;
Metotrexato
Istituto Giannina Gaslini-PRINTO
2005 - EUCTR2005-001086-34-ES Denmark;Italy;Spain;
NAPROXEN SODIUM
Pfizer Inc
- - EUCTR2014-003737-26-Outside-EU/EEA Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Ukraine;United States;
NI-0501
Novimmune SA
2018 Phase 2 EUCTR2016-004223-23-NL Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-004223-23-IT France;Germany;Italy;Netherlands;Spain;United Kingdom;
2017 Phase 2 EUCTR2016-004223-23-ES France;Germany;Italy;Netherlands;Spain;United Kingdom;
- Phase 2 EUCTR2016-004223-23-FR Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
Swedish Orphan Biovitrum AG
2017 Phase 2 EUCTR2016-004223-23-GB Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2021-001577-24-IT Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Swedish Orphan Biovitrum AG (Sobi AG)
2021 Phase 2;Phase 3 EUCTR2021-001577-24-PL Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2021-001577-24-ES Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2021-001577-24-SE Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2021-001577-24-FR Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2021-001577-24-CZ Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
NSAIDs
Hoffmann-La Roche
2018 Phase 4 NCT03301883 China;
Naproxen
AstraZeneca
2011 Phase 1 NCT01358383 United States;
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009 Phase 4 NCT00807846 Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Switzerland;Ukraine;United States;
Nicotinamide
UMC Utrecht
- Phase 1;Phase 2 EUCTR2016-003643-10-NL Netherlands;
Non-Biologic DMARDs
Hoffmann-La Roche
2000 - NCT02784808 -
Non-steroidal anti-inflammatory drugs (NSAIDs)
Hoffmann-La Roche
2008 Phase 3 NCT00642460 Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
Norditropin SimpleXx 5mg/1.5ml
Royal Hospital For Sick Children, Yorkhill Division
2004 - EUCTR2004-004153-25-GB United Kingdom;
NsNSAIDs
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009 - NCT00688545 United States;
OLE BSA Adalimumab +/- MTX
Abbott
2002 Phase 3 NCT00048542 Belgium;Czech Republic;France;Germany;Italy;Slovakia;Spain;United States;
OLE FD Adalimumab +/- MTX
Abbott
2002 Phase 3 NCT00048542 Belgium;Czech Republic;France;Germany;Italy;Slovakia;Spain;United States;
OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA
AMGEN INC.
2021 Phase 3 EUCTR2019-002788-88-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;
OTEZLA - 30 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/ALU) - 56 COMPRESSE
AMGEN INC.
2021 Phase 3 EUCTR2019-002788-88-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;
Olumiant
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 3 EUCTR2019-000119-10-IT European Union;France;Germany;Italy;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-IT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Eli Lilly and Company
2020 Phase 3 EUCTR2019-000119-10-DE France;Germany;Italy;Spain;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-GB France;Germany;United Kingdom;
2019 Phase 3 EUCTR2019-000119-10-FR France;Germany;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-PL Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-GB Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-FR Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-DK Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-DE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-CZ Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-BE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004518-24-AT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004495-60-PL Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004495-60-GB Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004495-60-FR Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004495-60-DK Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-PL Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-GB Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-FR Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-DK Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-DE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-CZ Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-BE Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
- Phase 3 EUCTR2017-004495-60-DE Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
- Phase 3 EUCTR2017-004495-60-CZ Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
- Phase 3 EUCTR2017-004495-60-BE Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
- Phase 3 EUCTR2017-004495-60-AT Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
- Phase 3 EUCTR2017-004471-31-AT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Lilly S.A.
2019 Phase 3 EUCTR2017-004518-24-ES Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
2019 Phase 3 EUCTR2017-004471-31-ES Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Oluminant
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 3 EUCTR2017-004518-24-IT Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Ondansetron
University of British Columbia
2019 - NCT04169828 Canada;
One Alpha Drops
Belfast Health and Social Care Trust, Musgrave Park Hospital
2006 Phase 4 EUCTR2005-003129-23-GB United Kingdom;
One-Alpha drops
Belfast Health and Social Care Trust, Musgrave Park Hospital
2006 Phase 4 EUCTR2005-003129-23-GB United Kingdom;
Orencia
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
Originator adalimumab
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2021 Phase 4 EUCTR2021-004031-86-IT Italy;
Otezla
Amgen Inc.
2021 Phase 3 EUCTR2019-002788-88-NL Austria;Belgium;France;Italy;Netherlands;
2021 Phase 3 EUCTR2019-002788-88-FR Austria;Belgium;France;Netherlands;
- Phase 3 EUCTR2019-002788-88-PL Austria;Belgium;France;Italy;Netherlands;Poland;
- Phase 3 EUCTR2019-002788-88-BE Austria;Belgium;Netherlands;
- Phase 3 EUCTR2019-002788-88-AT Austria;Belgium;France;Italy;Netherlands;
Pneumo23
Institut National de la Santé Et de la Recherche Médicale, France
2006 Phase 2/Phase 3 NCT00339157 France;
Profilassi per Herpes Zoster
Swedish Orphan Biovitrum AG
- Phase 2;Phase 3 EUCTR2021-001577-24-IT Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Quadrivalent HPV vaccine
The University of New South Wales
2007 Phase 3 NCT02263703 Australia;
RIL-1RA
University Medical Center Utrecht
2016 Phase 4 EUCTR2015-004393-16-NL Netherlands;
RO4877533
Roche Pharma AG
2011 - EUCTR2011-001097-25-DE Germany;
RO4877533 (TCZ)
F. Hoffmann-La Roche Limited
2008 - EUCTR2007-000872-18-SK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-SE Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-NL Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-ES Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-DK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2007-000872-18-NO Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
F. Hoffmann-La Roche Ltd.
2008 Phase 3 EUCTR2007-000872-18-GR Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2007-000872-18-GB Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-DE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-CZ Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-BE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
ROCHE
2008 - EUCTR2007-000872-18-IT Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
ROACTEMRA 20 mg/ml, concentrado para solución para perfusión
F. Hoffmann-La Roche Ltd
2009 Phase 3 EUCTR2009-011593-15-ES Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
RVG 104433
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
RVG 28636
University Medical Center Utrecht
2014 - EUCTR2013-003956-18-NL Canada;Germany;Latvia;Netherlands;United States;
Recombinant antihumanized anti-human monoclonal antibody directed against the IL-6R
F. Hoffmann-La Roche Ltd
2013 Phase 1 EUCTR2012-003490-26-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2012-003490-26-Outside-EU/EEA Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class
Novartis Farmacéutica S.A.
2009 Phase 3 EUCTR2008-005476-27-ES Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-ES Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-ES Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
Novartis Pharma Services AG
2010 - EUCTR2008-008008-42-GR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005479-82-GR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005476-27-GR Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2010 - EUCTR2008-005476-27-GB Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005479-82-FR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005479-82-BE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-005476-27-FR Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-SE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Russian Federation;Spain;Swaziland;Sweden;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-GB Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-008008-42-FR Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-DK Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008008-42-DE Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2009 - EUCTR2008-005479-82-SE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-HU Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-GB Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-DK Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-DE Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005479-82-AT Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-SE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-HU Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-DK Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-DE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-005476-27-BE Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-008008-42-NO Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-005479-82-NO Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2008-005476-27-NO Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
Recombinant humanized anti-human monoclonal antibody directed against the IL-6R
F. Hoffmann-La Roche Ltd.
2013 Phase 1 EUCTR2012-003486-18-PL Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2012-003486-18-Outside-EU/EEA Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
Reumaflex
IRCCS Istituto Giannina Gaslini
2019 Phase 3 EUCTR2018-001931-27-IT Italy;
Rilonacept
Montefiore Medical Center
2008 Phase 2 NCT00534495 United States;
Rilonacept (IL-1 Trap)
Regeneron Pharmaceuticals
2005 Phase 1 NCT01803321 United States;
Ro 487-7533/F01
F. Hoffmann-La Roche Ltd
2010 - EUCTR2009-011593-15-NL Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011593-15-GB Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 Phase 3 EUCTR2009-011593-15-BE Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 - EUCTR2009-011593-15-FR Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-011593-15-DE Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
Ro 487-7533/F10
University Hospitals Bristol NHS Foundation Trust
2015 Phase 2 EUCTR2015-001323-23-GB United Kingdom;
Ro 487-7533/F10-04
F. Hoffmann-La Roche Ltd
2014 Phase 1 EUCTR2013-005212-98-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 1 EUCTR2013-005212-98-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 1 EUCTR2013-005212-98-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
- Phase 1 EUCTR2013-005212-98-FR Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2012-003490-26-Outside-EU/EEA Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd.
2013 Phase 1 EUCTR2012-003486-18-PL Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2012-003486-18-Outside-EU/EEA Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
Roche Farma S.A. en nombre de F. Hoffmann-La Roche Ltd
2014 - EUCTR2013-005212-98-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States;
Ro-Actemra
Roche Pharma AG
2011 - EUCTR2011-001097-25-DE Germany;
RoActemra
F. HOFFMANN - LA ROCHE LTD.
2013 Phase 4 EUCTR2012-000444-10-IT Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
F. Hoffmann-La Roche Ltd
2014 Phase 1 EUCTR2013-005212-98-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 1 EUCTR2013-005212-98-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2010 - EUCTR2009-011593-15-NL Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011593-15-GB Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 Phase 3 EUCTR2009-011593-15-BE Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 - EUCTR2009-011593-15-IT Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-011593-15-FR Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-011593-15-DE Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd.
2013 Phase 1 EUCTR2012-003486-18-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2012 Phase 4 EUCTR2012-000444-10-SE Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-GB Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-ES Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-DE Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2007-000872-18-GB Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-DE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-CZ Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-BE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 4 EUCTR2012-000444-10-NO Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
Roche Farma S.A. en nombre de F. Hoffmann-La Roche Ltd
2014 - EUCTR2013-005212-98-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States;
Roche Pharma AG
2011 - EUCTR2011-001097-25-DE Germany;
University Hospitals Bristol NHS Foundation Trust
2015 Phase 2 EUCTR2015-001323-23-GB United Kingdom;
RoActemra/Actemra (tocilizumab)
Hoffmann-La Roche
2012 Phase 3 NCT01575769 Poland;Russian Federation;
SAR153191 (REGN88)
sanofi-aventis recherche & développement
2021 Phase 2 EUCTR2015-004000-35-IE Argentina;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2021 Phase 2 EUCTR2015-004000-35-BG Argentina;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2017 Phase 2 EUCTR2015-004000-35-PL Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2015-004000-35-NL Argentina;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2015-004000-35-GB Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2015-004000-35-DE Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2015-003999-79-DE Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004000-35-IT Argentina;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004000-35-FI Argentina;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004000-35-ES Argentina;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004000-35-EE Argentina;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003999-79-PL Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003999-79-NL Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003999-79-IT Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003999-79-FI Argentina;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003999-79-ES Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003999-79-CZ Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2015-004000-35-FR Argentina;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2015-004000-35-CZ Argentina;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2015-003999-79-GB Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2015-003999-79-FR Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2015-003999-79-EE Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2015-003999-79-Outside-EU/EEA Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
SB4 (etanercept biosimilar)
Samsung Bioepis Co., Ltd.
2013 Phase 3 EUCTR2012-005026-30-HU Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-PL Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-CZ Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-BG Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
SB5
Samsung Bioepis Co., Ltd
2015 - EUCTR2014-004887-39-PL Poland;
Samsung Bioepis Co., Ltd.
2014 Phase 3 EUCTR2013-005013-13-BG Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-PL Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-LT Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
SSGJ-613
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2021 Phase 1 NCT05027373 China;
SUB180983
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 3 EUCTR2019-000119-10-IT European Union;France;Germany;Italy;United Kingdom;
Sarilumab
Sanofi
2016 Phase 2 NCT02776735 Argentina;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Sarilumab SAR153191 (REGN88)
Sanofi
2018 Phase 2 NCT02991469 Argentina;Bulgaria;Canada;Chile;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Sedatives/Hypnotics,Other
University of Oulu
2017 Phase 4 NCT03069638 Finland;
Somatropin
Royal Hospital For Sick Children, Yorkhill Division
2004 - EUCTR2004-004153-25-GB United Kingdom;
Sulfasalazine
Pfizer
2010 Phase 4 NCT00637780 Canada;Mexico;United States;
TC-MSC
University Medical Center Utrecht
2014 - EUCTR2012-002067-10-NL Netherlands;
TNFR:Fc
Samsung Bioepis Co., Ltd.
2013 Phase 3 EUCTR2012-005026-30-HU Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-PL Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-CZ Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-BG Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
TRIAMCINOLONE HEXACETONIDE
Oslo University Hospital
2020 Phase 4 EUCTR2019-000889-38-NO Norway;
Taltz (80 mg solution for injection in pre-filled syringe)
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Eli Lilly and Company
2021 Phase 3 EUCTR2018-000681-10-CZ Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-GB Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DK Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DE Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-NL Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-FR Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-BE Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Tocilizumab
Clinical Immunology, Jichi Medical University
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 3 EUCTR2016-000312-15-FR France;
Assistance Publique - Hôpitaux de Paris
2017 Phase 3 NCT02840175 France;
Children's Hospital of Chongqing Medical University
2017 - ChiCTR-OPB-17013704 China;
2016 - ChiCTR-OPC-17011391 China;
Division of Rheumatology &
Eric B. Suhler
2013 Phase 1/Phase 2 NCT01603355 United States;
F. Hoffmann-La Roche Limited
2008 - EUCTR2007-000872-18-SK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-DK Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
F. Hoffmann-La Roche Ltd
2015 Phase 1 EUCTR2015-000435-33-PL Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-HU Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-GB Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-DE Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2015 Phase 1 EUCTR2015-000435-33-BE Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
2010 - EUCTR2009-011593-15-NL Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011593-15-GB Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 Phase 3 EUCTR2009-011593-15-BE Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 - EUCTR2009-011593-15-FR Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-011593-15-DE Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 1 EUCTR2015-000435-33-FR Argentina;Belgium;Canada;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd.
2012 Phase 4 EUCTR2012-000444-10-SE Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-GB Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-ES Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
2012 Phase 4 EUCTR2012-000444-10-DE Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2007-000872-18-GB Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-DE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-CZ Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
2008 - EUCTR2007-000872-18-BE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
- Phase 4 EUCTR2012-000444-10-NO Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
Hoffmann-La Roche
2018 Phase 4 NCT03301883 China;
2014 Phase 1 NCT02165345 Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 4 NCT01734382 Argentina;Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;United States;
2013 Phase 1 NCT01904292 Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 NCT01904279 Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2012 Phase 1 NCT01455701 Argentina;Belgium;Canada;France;Germany;Hungary;Poland;Russian Federation;Spain;United Kingdom;United States;
2009 Phase 3 NCT00988221 Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
ROCHE
2008 - EUCTR2007-000872-18-IT Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
Roche Farma S.A en nombre de F. Hoffmann-La Roche Ltd
2015 Phase 1 EUCTR2015-000435-33-ES Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
Shenzhen Children's Hospital
2017 - ChiCTR-INR-17011829 China;
Tufts Medical Center
2009 - NCT00868751 United States;
University Hospitals Bristol NHS Foundation Trust
2015 Phase 2 EUCTR2015-001323-23-GB United Kingdom;
University of Oklahoma
2009 - NCT00862758 United States;
Yokohama City University Hospital Department of Pediatrics
2016 - JPRN-UMIN000024178 Japan;
Tocilizumab Roche
F. Hoffmann-La Roche Limited
2008 - EUCTR2007-000872-18-SE Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-NL Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000872-18-ES Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2007-000872-18-NO Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
F. Hoffmann-La Roche Ltd.
2008 Phase 3 EUCTR2007-000872-18-GR Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
Tocilizumab SC
F. Hoffmann-La Roche Ltd
2014 Phase 1 EUCTR2013-005212-98-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 1 EUCTR2013-005212-98-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003490-26-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2012-003490-26-Outside-EU/EEA Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd.
2013 Phase 1 EUCTR2012-003486-18-PL Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-GB Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-ES Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 1 EUCTR2012-003486-18-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2012-003486-18-Outside-EU/EEA Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
Tocilizumab [RoActemra/Actemra]
Hoffmann-La Roche
2013 Phase 3 NCT01727986 Brazil;
2012 Phase 3 NCT01673919 France;
2012 Phase 3 NCT01667471 Germany;
2008 Phase 3 NCT00642460 Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
Tofacitinib
PFIZER INC.
2013 - EUCTR2011-004915-22-IT Argentina;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;
2012 - EUCTR2011-004914-40-IT Argentina;Hungary;Italy;Mexico;Poland;Russian Federation;
Pfizer
2013 Phase 3 NCT01500551 Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Hungary;Israel;Mexico;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc
2012 Phase 2;Phase 3 EUCTR2011-004915-22-SK Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2012 Phase 1 EUCTR2011-004914-40-HU Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
2012 - EUCTR2011-004914-40-SK Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
2012 - EUCTR2011-004914-40-PL Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
2018 Phase 2;Phase 3 EUCTR2011-004915-22-BE Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-004915-22-PL Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-004915-22-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-004915-22-HU Czech Republic;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Slovakia;
- Phase 2;Phase 3 EUCTR2011-004915-22-NL Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc.
2018 Phase 2;Phase 3 EUCTR2011-004915-22-GB Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Tofacitinib citrate
PFIZER INC
2020 Phase 3 EUCTR2017-002018-29-IT Argentina;Belgium;Brazil;Canada;Chile;China;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
- Phase 2;Phase 3 EUCTR2011-004915-22-SE Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Tofacitinibe citrate
Pfizer Inc
2012 Phase 2;Phase 3 EUCTR2011-004915-22-SK Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
2018 Phase 2;Phase 3 EUCTR2011-004915-22-BE Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc.
2020 Phase 3 EUCTR2017-002018-29-SK Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc. 235 East 42nd Street, New York, New York 10017
2022 Phase 3 EUCTR2017-002018-29-HU Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-NL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2017-002018-29-DE Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2017-002018-29-PL Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-SE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-002018-29-BE Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Triamcinolone Hexacetonide 20 MG/ML
Oslo University Hospital
2020 Phase 4 NCT04614311 Norway;
Upadacitinib
ABBVIE DEUTSCHLAND GMBH & CO. KG
2019 Phase 1 EUCTR2018-000715-25-IT Germany;Hungary;Italy;Spain;United States;
AbbVie
2019 Phase 1 NCT03725007 Germany;Hungary;Israel;Italy;Puerto Rico;Spain;United States;
AbbVie Deutschland GmbH & Co. KG
2019 Phase 1;Phase 3 EUCTR2018-000715-25-ES Germany;Hungary;Italy;Spain;United States;
2019 Phase 1 EUCTR2018-000715-25-HU Germany;Hungary;Italy;Spain;United States;
2019 Phase 1 EUCTR2018-000715-25-DE Germany;Hungary;Italy;Spain;United States;
VIMOVO 250/20
Horizon Pharma Ireland, Ltd., Dublin Ireland
2012 Phase 4 NCT01544114 United States;
VIMOVO 375/20
Horizon Pharma Ireland, Ltd., Dublin Ireland
2012 Phase 4 NCT01544114 United States;
VIMOVO 500/20
Horizon Pharma Ireland, Ltd., Dublin Ireland
2012 Phase 4 NCT01544114 United States;
VSL#3
Assistance Publique - Hôpitaux de Paris
2017 - NCT03092427 France;
Vitamin B3
UMC Utrecht
2019 Phase 1;Phase 2 EUCTR2018-002245-11-NL Netherlands;
Yellow Fever vaccine (17D)
University of Sao Paulo General Hospital
2018 - NCT03430388 Brazil;
ibuprofen/26.6 mg famotidine
Horizon Pharma Ireland, Ltd., Dublin Ireland
2012 Phase 4 NCT01563185 United States;